





The Activity of the JAK-STAT Pathway in Infantile Haemangioma 
and the Haemogenic Potential of Infantile Haemangioma 
Explant Derived Cells 
 
A thesis submitted in  
fulfilment of the requirements  
for the degree of 
 



















Lucy Isabelle Sulzberger 
University of Otago 
 
Supervised by Drs Swee T. Tan and Paul F Davis, Gillies McIndoe Research Institute and 








Background: Stem cells have been identified within proliferating infantile haemangioma (IH), 
the most common tumour of infancy, and have been demonstrated to play a critical role in the 
rapid proliferation and gradual involution of this tumour. There is accumulating evidence 
showing that IH is caused by aberrant proliferation and differentiation of a haemogenic 
endothelium (HE). This HE possesses a functional capacity to undergo primitive 
erythropoiesis in vitro. Short chain fatty acid (SCFA) derivatives have been shown to stimulate 
cell proliferation and induce STAT-5 activation in various haematopoietic cell lines.  
Aims: The aims of this study were to investigate (1) the activity of the components of JAK-STAT 
pathway within the three phases of IH development; (2) the haematopoietic capacity of IH in 
vitro; and (3) the effects of SCFAs, butyric acid and propionic acid, to induce erythroid 
differentiation of explant-derived cells (IHEDCs) in culture. 
Methods: The presence of pSTAT proteins in proliferating, involuted and involuting IH were 
investigated using 3,3'-diaminobenzidine (DAB) and immunofluorescent (IF) 
immunohistochemical (IHC) staining, 1-DE Western Blotting, and NanoString analysis. 
Proliferating IH explants were cultured using an in vitro model and the IHEDCs emanating from 
the explants were harvested. Cell suspension of volume equivalent to 5x105 live cells was plated 
on Matrigel and incubated in 0.05-1mM butyric acid, RPMI and 0.05-1mM propionic acid, and 
0.05M DMSO (positive control) in each of RPMI media only, RPMI enriched with iron and MCDB 
media. Media was changed daily and cells were extracted and quantified following 24-72 hours 
in culture. Differentiated IHEDCs were characterised by IF immunocytochemical (ICC) staining 
with glycophorin-A. 
Results: Protein and genomic data reveal the expression of STATs 1, 3 and 5 which are activated 
in IH, particularly in the proliferative phase, with expression tapering as the lesion involutes. 
pSTAT3 is expressed most abundantly with  pSTAT5 the least abundant. Low concentrations of 
both butyric acid and propionic acid significantly increased proliferation and differentiation of 
IHEDCs into blast colonies and the production of bi-concave cells within 72 hours in culture. 
These enucleated bi-concave cells expressed the erythrocyte-specific marker, glycophorin-A.  
Conclusion: The findings of SCFAs promoting proliferation and differentiation of IHEDCs into 





haematopoietic differentiation, possibly via pSTAT-5 signalling. IH offers a simple and novel in 






I would like to express my sincere gratitude to my supervisors at Gillies McIndoe Research 
Institute (GMRI): Dr Swee T. Tan, Dr Paul Davis and Dr Tinte Itinteang for their direction over 
the course of my studies. I am incredibly grateful for the opportunity to work in the GMRI 
environment and for the support, guidance and mentorship that has so generously been given 
throughout my time there. Likewise, I am indebted to all the staff of the GMRI for their 
assistance in making my project happen. To be a member of such a team, even for a short time, 
is an experience I have not taken for granted. 
I would also like to acknowledge the support of my university supervisor, Professor Dawn Elder, 
for her assistance throughout this project. I very much appreciate Professor Elder’s time made 
available to me during her busy schedule to discuss writing progress. 
Furthermore, I would like to express my utmost appreciation for the generous scholarships I 
have received to support this work: Otago University Tassell Scholarship, Freemasons Charity 
University Scholarship and the Deane Endowment Trust Kirsten Deane Scholarship and Deane 







Table of Contents 
Abstract ........................................................................................................................... iii 
Acknowledgements ........................................................................................................... v 
Table of Contents ............................................................................................................. vi 
List of Figures ................................................................................................................. viii 
List of Tables ..................................................................................................................... x 
List of Abbreviations  ....................................................................................................... xi 
Chapter 1 Introduction ..................................................................................................... 1 
1.1 Background ...................................................................................................................... 1 
1.2 Infantile Haemangioma ................................................................................................... 3 
1.3 Human Haematopoiesis .................................................................................................. 9 
1.4 Aims ................................................................................................................................ 36 
1.5 Hypotheses ..................................................................................................................... 36 
Chapter 2 Materials and Methods .................................................................................. 37 
2.1 Materials ......................................................................................................................... 37 
2.2 Methods ......................................................................................................................... 48 
Chapter 3 Results: JAK-STAT Pathway in Infantile Haemangioma .................................... 62 
3.1 STAT1 in Infantile Haemangioma STAT1 in Infantile Haemangioma........................... 62 
3.2 STAT3 in Infantile Haemangioma .................................................................................. 69 
3.3 STAT3 and STAT5 mRNA Levels in Infantile Haemangioma ......................................... 75 
3.4 STAT5 in Infantile Haemangioma .................................................................................. 77 
Chapter 4 Results: Infantile Haemangioma Explant Culture and Differentiation of IHEDCs83 
4.1 In Vitro Culture of Infantile Haemangioma Explant Tissue .......................................... 84 
4.2 IHEDCs in Culture with Short Chain Fatty Acids ........................................................... 85 
4.3 Light Microscopy of IHEDCs in Culture with Administration of Short Chain Fatty Acids
 ……………………………………………………………………………………………………………………………….85 
4.4 Characterisation of IHEDCs in Culture Following Administration of Propionic Acid .. 87 
4.5 Quantitation of the Proliferative Effect of Short Chain Fatty Acids on IHEDCs in     
Culture  ………………………………………………………………………………………………………………...88 
Chapter 5 Discussion ...................................................................................................... 93 
5.1 Interpretation of the Findings of This Study ................................................................. 93 
5.2 Limitations of This Study ............................................................................................. 100 





5.4 Significance of the Findings of this Study ................................................................... 103 







List of Figures 
Figure 1-1 Infantile haemangioma (IH) at 2 weeks, 2 months, 4 months and 6 years. ..............  3 
Figure 1-2 Bi-concave cells from proliferating IH explant culture at 5 months. .......................... 9 
Figure 1-3 Onset of primitive and definitive haematopoiesis ..................................................... 10 
Figure 1-4 Blast-colony forming cells (BL–CFC) and embryoid body (EB) isolated from hESC 
culture. ........................................................................................................................................... 15 
Figure 1-5 Endothelial and haematopoietic molecular markers haematopoietic precursor 
populations.. .................................................................................................................................. 19 
Figure 1-6 Endothelial and haematopoietic precursors from primitive mesoderm. ................. 22 
Figure 1-7 Endothelial core structures and mature haemangioblast colonies  ......................... 22 
Figure 1-8 The JAK-STAT pathway. ............................................................................................... 26 
Figure 3-1 IF IHC of pSTAT1 in IH. ................................................................................................. 64 
Figure 3-2 DAB IHC of pSTAT1in IH.. ............................................................................................. 65 
Figure 3-3 DAB IHC of pSTAT1 and GLUT-1 in IH.. ....................................................................... 66 
Figure 3-4 DAB IHC of pSTAT1 and SMA in IH. ............................................................................. 67 
Figure 3-5 Western Blot of pSTAT1 in IH. ..................................................................................... 68 
Figure 3-6 IF IHC of pSTAT3 and CD34 in IH. ................................................................................ 70 
Figure 3-7 DAB IHC of pSTAT3 in IH.. ............................................................................................ 71 
Figure 3-8 DAB IHC of pSTAT3 and GLUT-1 in IH.. ....................................................................... 72 
Figure 3-9 DAB IHC of pSTAT3 and SMA in IH. ............................................................................. 73 
Figure 3-10 Western Blotting of pSTAT3 in  IH. ........................................................................... 74 
Figure 3-11 STAT3 and STAT5 mRNA levels in IH.. ....................................................................... 75 
Figure 3-12 IF IHC of pSTAT1 and GLUT-1 in IH. .......................................................................... 78 
Figure 3-13 DAB IHC of pSTAT1 in IH.. .......................................................................................... 79 
Figure 3-14 DAB IHC of pSTAT5 and GLUT-1 in IH. ...................................................................... 80 
Figure 3-15 DAB IHC of pSTAT1 and SMA in IH ............................................................................ 81 
Figure 3-16 Western Blotting of pSTAT5 in IH ............................................................................. 82 
Figure 3-17 Western Blotting of total STAT5  in IH. ..................................................................... 82 
Figure 4-1 IHEDCs arising from proliferating IH explants.  .......................................................... 84 
Figure 4-2 IHEDCs cultured in the presence of SCFAs ................................................................. 86 
Figure 4-3 IHEDCs in culture with 0.1mM propionic acid. .......................................................... 87 
Figure 4-4 IF ICC staining of bi-concave structures at 72 hrs with 0.1mM propionic acid ........ 87 
Figure 4-5 Viable IHEDC counts at 24 hrs in culture with SCFAs................................................. 90 





Figure 4-7 Viable IHEDC counts at 24 hrs in culture with SCFAs................................................. 92 






List of Tables 
Table 2.1. Demographic Details of Patients Whose IH Tissues were Used for This Study .......  37 
Table 2.2 Primary and Secondary Antibodies; Species, Sources, Concentrations and Control 
Tissues ............................................................................................................................................ 38 
Table 2.3 Autostainer Kits for Immunohistochemical Staining  .................................................. 40 
Table 2.4 Consumables used for 1DE-Western Blotting  ............................................................ 41 
Table 2.5 RNA Extraction Kits ........................................................................................................ 41 
Table 2.6 Chemicals, Reagents and Stains ................................................................................... 42 
Table 2.7 Plastic- and Glass-ware ................................................................................................. 44 
Table 2.8 Laboratory Equipment and Their Sources ................................................................... 46 
Table 2.9 Leica Autostainer F Protocol - Routine IHC Staining ..................................................  54 
Table 2.10 Leica Autostainer TF Protocol – Long Antibody Incubation ...................................... 54 
Table 2.11 Leica Autostainer J Protocol – DAB IHC Staining for Using Two Primary Antibodies 
 ........................................................................................................................................................ 55 
Table 2.12 Leica Autostainer IF Protocol – IF IHC Staining Using Two Antibodies ..................... 56 
Table 2.13 Deparrifinisation and Re-hydration for Manual IF IHC .............................................. 57 
Table 2.14 Formulation of 10x TBS Buffer ................................................................................... 58 
Table 2.15 Formulation of Sodium Citrate Buffer ........................................................................ 58 
Table 2.16 Haematoxylin and Eosin Staining Protocol ................................................................ 59 








List of Abbreviations 
1DE-WB 1 dimensional electrophoresis Western Blot 
α-ABA Alpha-amino-N-butyric acid 
ACE Angiotensin converting enzyme 
AGM Aorta-gonad-mesonephros 
AHP Angiogenic haematopoietic progenitor 
Ang2 Angiopoietin 2 
ATII Angiotensin II 
ATIIR1 Angiotensin II receptor 1 
ATIIR2 Angiotensin II receptor 2 
BFU-E Erythroid burst forming unit 
BL-CFC Blast-colony forming cell 
BSA Bovine serum albumin 
CD Cluster of differentiation 
C-FMS Colony stimulating factor receptor 1 
CSC Cancer stem cell 
DAB 3,3'-diaminobenzidine 
DAPI 4', 6-diamidino-2-phenylindole 
DAPI 4',6-diamidino-2-phenylindole 
Dil-LDL Dil-conjugated low density lipoprotein 
DMSO Di-methyl sulfoxide 
EC Endothelial cell 
EGF Epidermal growth factor 
EPC Endothelial precursor cell 
EPO Erythropoietin 
EPO-R Erythropoietin receptor 
ESC Embryonic stem cell 
FFPE Formalin-fix paraffin-embedded  
FGF-2 Fibroblast growth factor-2 
G-CSF Granulocyte colony stimulating factor 
GFP Green fluorescent protein 
GMRI Gillies McIndoe Research Institute 
HbF Foetal haemoglobin 
HbSS Sickle cell disease  
HBZ Embryonic haemoglobin ζ 
hCG Human chorionic gonadotropin 
HE Haemogenic endothelium 
HEP Haemogenic endothelium precursor 
hESC Human embryonic stem cell 
HLA-G Human leucocyte antigen-G  
hPL Human placental lactogen 
HVMP Haematovascular mesodermal precursors  
ICC Immunocytochemistry 
IF Immunofluorescent  
IFN Interferon 
IGF-I Insulin-like growth factor I 





IH Infantile haemangioma  
IHC Immunohistochemical 
IHEC Infantile haemangioma endothelial cell 
IHEDC Infantile haemangioma explant derived cell 
IHMSC Infantile haemangioma mesenchymal stem cell 




iPSC Induced pluripotent stem cell 
JAK Janus kinase 
KDR Kinase insert domain receptor 
LIF Leukaemia inhibitory factor 
MALDI Matrix-assisted laser desorption/ionization 
MEDEP Mouse ESC-derived erythroid progenitor 
MEL Murine erythroleukaemia 
MSC Mesenchymal stem cell  
non-HEP Non-haemogenic endothelium precursor 
OPG Osteoprotegerin 
PBS Phosphate buffered saline 
PCNA Proliferating cell nuclear antigen 
PDGFR-α Platelet-derived growth factor receptor-α 
PECAM-1 Platelet endothelial cell adhesion molecule-1 
Pref-1 Preadipocyte factor 1 
PVDF Polyvinylidene Difluoride 
 RAS Renin angiotensin system 
RH Relative humidity 
RIPA Radioimmunoprecipitation assay 
RPMI Roswell Park Memorial Institute 
RT-PCR Real time-polymerase chain reaction  
RTU Ready to use 
SCF Stem cell factor 
SCFA Short chain fatty acid 
SCL Stem cell leukaemia 
Ser727 Serine residue 727 
SMC Smooth muscle cell 
SOCS Suppressor of cytokine signalling  
STAT Signal transducer and activator of transcription 
TBS Tris buffered saline 
TBST TBS with 0.1% Tween 20 
TOF Time-of-flight 
TR-1fR Transferrin receptor-1 
TRAIL Tumour-necrosis factor-related apoptosis-inducing ligand 
TRAIL-R2 Tumour-necrosis factor-related apoptosis-inducing ligand receptor 
2 VEGF Vascular endothelial growth factor  
VEGFR-1 Vascular endothelial growth factor receptor 1 
VEGFR-2 Vascular endothelial growth factor receptor 2 
WB Western Blot 




1 Chapter 1 Introduction 
1.1 Background  
Blood transfusion therapy is regularly utilised with more than 80 million human-to-human 
transfusions worldwide annually1 with each containing approximately 1012 mature 
erythrocytes2. Reports of the transfusion of blood products date as far back as the 15th 
century3. However, despite vast improvements in the field and increasingly stringent protocol 
regarding the collection, screening, storage, and administration of human blood products, 
human-to-human blood transfusion remains a costly treatment modality with associated risks. 
These shortfalls have prompted much investigation into potential ex vivo haematopoietic 
production to negate human blood donation.  
In recent decades, with an increase in stem cell research, many groups have sought to achieve 
efficient and cost effective production of blood products ex vivo. This includes the use of 
human embryonic stem cells (hESC)4 and animal embryonic stem cells5, erythroid precursors 
from umbilical cord blood6, and more recently induced pluripotent stem cells (iPSCs)7-12 from 
adult human cells. In a 2013 review Kyba et al.13 referred to “that holy grail, the generation of 
repopulating haematopoietic stem cells in vitro from induced pluripotent stem cells”. It is, 
however, recognised that ex vivo production capability is limited by current understanding of 
haematopoietic development14. Improved knowledge of the molecular pathways that 
modulate the hierarchical development of haematopoiesis is required to maximise ex vivo 
capability.  
In other fields of medical science, a role for primitive cells within tumour biology is now 
increasingly realised. Infantile haemangioma (IH), the most common tumour of infancy15 has 
been shown to be caused by an aberrant proliferation and differentiation of a haemogenic 
endothelium (HE)16 with a capacity for endothelial17, mesenchymal18, 19, neuroglial18 and 
haematopoietic20 differentiation. Stem cells of these lineages have also been demonstrated 
within IH including mesenchymal stem cells (MSCs)17, 19, 21 and endothelial precursor cells 
(EPC)22. The demonstration of haemogenic activity within IH16, 20, alongside the success of in 
vitro IH explant culture23, shows that IH is a useful model for the in vitro study of human 
haematopoiesis.  




The present study uses IH explant culture to further demonstrate (1) the expression and 
activity of the components of the JAK-STAT pathway in IH; (2) the haemogenic potential of IH 
in vitro; and (3) the effects of short chain fatty acids (SCFAs), to induce erythroid differentiation 
of IH explant-derived cells (IHEDCs) in the culture. 
  




1.2 Infantile Haemangioma  
1.2.1 Clinical Features  
IH affects up to 10% of infants, being the most common tumour of infancy15. Considered a 
benign tumour of the microvasculature, IH typically exhibits a programmed biologic behaviour 
with rapid proliferation during infancy (Fig. 1.1 A-C) and spontaneous slow involution involving 
gradual replacement of the cellular elements with a fibro-fatty residuum (Fig. 1.1D) over a 
period of up to 10 years15, 24.  The incidence of IH is higher in Caucasian25, female25-28, low birth 
weight and premature29, 30 infants and those who received erythropoietin (EPO) treatment (for 
anaemia of prematurity)31.  The incidence of IH is also increased in infants born following 
multiple gestation pregnancy32, amniocentesis33, chorionic villous sampling33 and pre-
eclampsia34.  
    
Figure 1-1. A proliferating infantile haemangioma in a chid aged 2 weeks (A), 2 months (B) and 
4 months (C). The same child at 6 years of age with an involuted lesion consisting a fibro-fatty 
residuum (D). (Courtesy of Dr Swee T. Tan) 
Most IH present as discrete lesions involving the skin and/or subcutaneous tissue24, 25, 35.A 
subgroup of IH are distributed in a segmental manner, with some associated with midline 
structural anomalies, constituting PHACES syndrome 34, 36 . IH does not show any genetic 
pattern37.  
1.2.1.1 β-Blockers and Infantile Haemangioma 
In 2008, propranolol38, a non-selective β-blocker; and acebutalol39, a predominantly β1-
blocker, were serendipitously discovered to induce accelerated involution of IH. At the 
empirical dosage of 2-3mg/kg/day, propranolol is now the preferred treatment for problematic 
proliferating IH 40, 41 , with other β-blockers including timolol42, nadolol43, and atenolol44 having 
also emerged. 
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Various mechanisms by which β-blockers induce involution of IH have been proposed. One 
hypothesis proposes its effect being mediated via vasoconstriction, based on the observed 
change in the colour and texture of the lesion immediately following initiation of propranolol 
treatment45. Another hypothesis postulates down-regulation of the RAF-mitogen activated 
protein kinase pathway, which in turn promotes down-regulation of vascular endothelial 
growth factor (VEGF) and fibroblast growth factor-2 (FGF-2) genes to induce accelerated 
involution46, 47. Others have suggested that β-blockers induce apoptosis of IH capillary 
endothelial cells (ECs)48. However, proof of these hypotheses is currently lacking. 
1.2.1.2 The Renin Angiotensin System and Infantile Haemangioma  
Itinteang et al.49 recently demonstrate that the endothelium of proliferating IH expresses 
components of the renin angiotensin system (RAS) and provide evidence supporting a crucial 
role for the RAS in the biology of IH that accounts for its spontaneous and β-blocker-induced 
accelerated involution. Furthermore, renin levels are higher in Caucasian50, premature51 and 
female52 infants, corresponding to the higher incidence of IH amongst these demographic 
groups25-27, 29, 30. Renin levels are 14 times higher at birth than in adulthood, and seven times 
higher at one year of age; adult levels of renin are reached at 10 years of age53. 
Angiotensin-converting enzyme (ACE) and angiotensin II receptor 2 (ATIIR2) have been 
suggested to be potential therapeutic targets for the treatment of IH49. A recent observational 
clinical study has shown the efficacy of captopril, an ACE inhibitor, in the treatment of 
problematic proliferating IH54. The discovery of the critical role of the RAS in IH provides a novel 
understanding of IH, human development, and other tumours in general.  
1.2.2 In Vitro Model of Infantile Haemangioma  
Early studies of IH used animal models or the isolation and subsequent culture of IH-derived 
cells. ‘Haemangioma’ has been induced through administration of T-oncogene transformed 
murine ECs, which disrupt normal vasculature and recruit host ECs in a number of species55. 
This model is embryonically and neonatally fatal and is dependent on the ongoing presence of 
the murine ECs55, limiting its application in the study of human IH which is present exclusively 
in early life. A similar model resulted in a 100% success rate through administration of the 
transgenic murine haemangioendothelioma cell line PY-4-156. Other investigators have used 
ECs derived from murine ‘haemangioma’ 57, 58  in culture. Engraftment of human IH tissue onto 




estradiol-treated nude mice has also been reported, with consequent lesion maintenance, 
capillary formation and proliferation of ECs59.   However, none of these models represents a 
true human model of IH. In 2000, Tan et al.23 described a serum-free in vitro human model of 
IH in which tissue explants are embedded between two layers of fibrin gel in culture, 
recapitulating many in vivo characteristics of the tumour.  
1.2.3 The Origin of Infantile Haemangioma  
Multiple theories of the origin for IH have been proposed. As early as 1863, Rudolf Virchow60, 
a German pathologist suggested that IH developed from inappropriately located embryonic 
mesenchyme. In 1950 it was suggested that IH results from embryonic sequestrations of 
mesenchymal angioblasts which failed to connect with other developing vascular networks61.   
More recently the isolation and purification IH cells and development of a human in vitro 
culture model have advanced the understanding of this enigmatic condition. Itinteang et al.62 
demonstrate that the endothelium of IH expresses markers consistent with a neural crest 
phenotype including p75, and transcription factors, SOX-9 and SOX-10, along with 
mesenchymal markers, CD29 and vimentin. The same cells have been shown to also express 
CD31 (also known as PECAM-1), VEGFR-2 (also known as KDR), CD34 as well as human 
chorionic gonadotropin (hCG) and human placental lactogen (hPL), markers of placental 
chorionic villi62. The absence of trophoblast markers, CK7 and human leucocyte antigen-G 
(HLA-G), suggests the origin of IH being the inner mesenchymal core cells of the placental 
chorionic villi, derived from the same primitive mesoderm that produces the yolk sac blood 
islands62, 63. Expression of the MSC marker, Pref-1 (an inhibitor of adipocyte differentiation), 
on the endothelium of IH19, leads Itinteang et al.18 to suggest that the preferred differentiation 
pathway toward adipocyte phenotype being inhibited during the proliferating phase of IH19. 
These cells are believed to be responsible for the spontaneous adipogenesis during IH 
involution, challenging previously accepted dogma of the recruitment of MSCs from adjacent 
niches. 
Itinteang et al.19 further suggest that IH results from an embolism of mesenchymal derived ECs 
through the umbilical vein during the early embryonic period. This concept is supported by the 
clinical observation of increased incidence of IH in pregnancies associated with placental 
events, such as placental chorionic villous sampling33 and amniocentesis33.  




1.2.4 Cellular Elements of Infantile Haemangioma 
1.2.4.1 Endothelial Cells  
ECs lining the capillaries of IH are phenotypically more similar to foetal than neonatal 
equivalents64 , that they are clonal is believed by some groups to indicate a somatic cellular 
defect65 or the potential for the lesion to arise from a single progenitor cell66.  
An early study, presented evidence supporting a crucial role for SPARC, a Ca2+ binding 
glycoprotein in the establishment of IH58. SPARC has been suggested to promote the 
detachment of host ECs from their normal environment and their subsequent migration to and 
integration with the disorganised capillary network58.  
Transcriptional profiling shows VEGFR-1, VEGFR-2, TIE-1, TIE-2 and angiopoietin 2 (ATII), to be 
highly expressed by IH ECs (IHECs) and IH tissue67. TIE-2 mRNA expression has been reported 
to be particularly high in IHECs leading to the conclusion that altered signalling through the 
angiopoietin system, for which TIE-2 is a receptor, may play a role in the pathogenesis of IH67. 
Whilst mutations in angiopoietin signalling have been reported in other hereditary68 and 
sporadic69 vascular anomalies, TIE-2 mutations have not been identified in IH. 
EPCs are a rare cell type found in the peripheral circulation and have the ability to differentiate 
into ECs thus contributing to angiogenesis in vivo. EPCs have been identified in IH22 with higher 
circulating levels in affected infants70. Yu et al.22, using mRNA studies and Northern blot 
analysis, demonstrate a CD34+/CD133+/VEGFR-2+/CD45- EPC population as an innate 
component of proliferating IH and suggest that such cells contributed to the rapid proliferative 
phase of IH. Isolation of these EPCs with subsequent culture reveals increased proliferation in 
the presence of the angiogenesis inhibitor, endostatin71. A similar effect in cord-blood derived 
EPCs, but not mature ECs, has been demonstrated suggesting that EPCs of IH are more like 
their foetal rather than adult counterparts71.  
1.2.4.2 Stem Cells in Infantile Haemangioma  
Further to their demonstration of EPCs in IH, Yu et al.18 identify another distinct CD133+ 
population which expresses neither CD34 nor haematopoietic markers. This CD133+/CD34-
/VEGFR-2- population has been characterised as IH MSCs (IHMSCs) and deemed responsible 
for the fibro-fatty residuum of involuted IH. A random X inactivation pattern seen in this 
population suggests that unlike IHECs, IHMSCs are not a clonal population18. IHMSCs have been 




further characterised and shown to express the MSC markers, CD105, CD90, CD29 and 
vimentin; whilst lacking the haematopoietic marker, CD45; and endothelial markers, CD34, 
CD31 and VEGFR-1, which were expressed by the more differentiated cells within IH21.  
Another CD133+ population, the IH stem cells (IHSCs) comprises just 0.2% of the lesion, and 
unlike IHMSCs, express endothelial markers including VEGFR-217. Unlike IHMSCs, IHSCs are 
capable of recapitulating GLUT-1+ IH in immune deficient mice whilst but can be differentiated 
down endothelial, neural, adipocytic, osteocytic and chondrocytic lineages17. This suggests that 
the IHMSC population is down-stream from the IHSC population. Expression of ESC markers, 
Nanog, and Oct-472; and mesenchymal markers, CD29 and CD4473, has also been 
demonstrated on CD133+ IHSCs. Immunofluorescent (IF) immunohistochemical (IHC) staining 
and flow cytometry have demonstrated that CD133+ IHSCs are localised to the perivascular 
region of proliferating IH21.   
1.2.4.3 Haemogenic Endothelium in Infantile Haemangioma  
In a series of publications in 2010 and 2011 Itinteang et al.16, 19, 20, 49, 62, 74, 75 have elucidated a 
great deal about the biology and cellular origin of IH using IF IHC staining and 
immunocytochemical staining (ICC), IH explant culture (as described by Tan et al. 2000), 
Western Blotting (WB), real time-polymerase chain reaction (RT-PCR) and IHEDC culture. This 
work includes evidence of a placental origin of IH, and the presence of a functional HE in IH, 
both in vivo and ex vivo.  
The expression of primitive mesodermal marker, brachyury; and the primitive haematopoietic 
markers, GATA-2, Tal-1 (also known as SCL) and ACE, by the CD34+/VEGFR-2+ IHECs points to a 
HE-derived haemangioblast precursors16. Nuclear localisation of Tal-1, the expression of 
embryonic haemoglobin ζ (HBZ) and EPO receptor (EPOR), in these cells indicate primitive 
haematopoiesis16, with production of primitive erythrocytes which stained positively for the 
erythrocyte-specific marker, glycophorin-A. IHC staining also reveals formation of blast-like in 
vitro derived from IHEDCs, and that they co-express CD34, CD133, VEGFR-2 and ACE, 
consistent with a haemangioblast-derived EPC phenotype49.  
HBZ, the embryonic haemoglobin α-chain equivalent, is present in the developing embryo until 
a switch to foetal haemoglobin at 6 weeks gestation76. Both HBZ77 and EPOR78 are expressed 
in the extra-embryonic yolk sac blood islands, the site of primitive haematopoiesis that occurs 
in the first trimester of pregnancy. Such links add weight to the speculated function of the 




previously reported HE lining the immature capillaries of proliferating IH.  Other groups have 
demonstrated that cells of the myeloid lineage arise alongside erythrocytes in developing 
primitive blood islands79, with Itinteang et al.20 suggesting that the mesodermal precursors 
that give rise to the IH-derived erythrocytes in vitro, may also be capable of giving rise to cells 
of the myeloid lineage within IH. 
Interestingly, haematopoiesis within the placental chorionic villi, the proposed origin of IH, has 
been suggested following ICC investigation80 whilst haemangioblastic activity within the 
chorionic villi has also been reported81.  
1.2.4.4 Innate Modulation of Infantile Haemangioma  
Itinteang et al.49 have demonstrated the expression of the components of the RAS, ACE and 
ATIIR2, on the endothelium of IH. Interestingly angiotensin II receptor 1 (ATIIR1) was not 
expressed on endothelium of the microvessels of IH. Furthermore, administration of ATII, the 
down-stream vasoactive peptide of the RAS, leads to increased proliferation of IHEDC-derived 
blast-like structures in culture49.  
Itinteang et al.74 also demonstrate expression of tumour-necrosis factor-related apoptosis-
inducing ligand (TRAIL) and its decoy death receptor osteoprotegerin (OPG) by the 
endothelium of proliferating IH. OPG acts as a soluble decoy death receptor, and is thought to 
protect cells from the apoptosis-inducing effects of TRAIL.  
The expression of ATIIR2 has been proposed to induce apoptosis in a number of tumour cell 
lines82-85. Gene profiling in human prostate cancer cells reveal that ATIIR2 over-expression 
result in up-regulation of TRAIL receptor 2 (TRAIL-R2) and other apoptosis-related genes86. 
Conversely ATII has been proposed to increase expression of OPG, the TRAIL decoy death 
receptor, and consequently prolong cell survival87.  
1.2.5 Infantile Haemangioma as A Model for Human Haematopoiesis  
As detailed above proliferating IH has recently been demonstrated as haematopoietically 
active20. The endothelium lining the immature capillaries of IH has been shown to express 
transcription factors associated with primitive haematopoiesis, EPOR, and the α-globin-like 
embryonic HBZ16. In support of this histochemical evidence, in vitro explant culture reveals 
production of primitive erythrocytes (Fig.1.2), hence confirming the haemogenic potential of 
proliferating IH20. 





Figure 1-2. Bi-concave cells observed after 5 months of proliferating IH explant culture. Cells 
are immunoreactive for the erythrocyte-specific protein glycophorin A (green) and negative 
for the haematopoietic transcription factor GATA-1 (blue). (Courtesy of Dr T. Itinteang).  
Itinteang et al.75 have shown evidence that the endothelium of IH is derived of 
haemangioblastic cells with a placental chorionic villous mesenchymal core cell origin. This 
corresponds with the demonstration of the activity of haemangioblasts in chorionic villi 
development88. Whilst it remains to be definitively proven that haemangioblasts proceed 
through an endothelial stage in order to produce haematopoietic cells, the blast-like structures 
arising from the IHEDCs are morphologically and functionally similar to those produced down-
stream of haemangioblasts in other studies using different models of haematopoiesis. 
Itinteang et al.49 have demonstrated that these blast-like structures possess a phenotype 
consistent with an EPC origin. This adds further evidence to the activity of haemangioblasts in 
IH as EPCs are endothelial progeny of haemangioblasts16, 89. Whilst the full haematopoietic 
potential of IHEDCs remains to be investigated, proliferating IH explants are a justified in vitro 
human model of primitive haematopoiesis.  
1.3 Human Haematopoiesis 
Haematopoiesis, the production of blood cellular components, is a complex and life-long 
process initiated during the first trimester of pregnancy within three weeks of conception90. 
Haematopoiesis consists of two distinct components: primitive haematopoiesis and definitive 
haematopoiesis (Fig.1.3). The exact phenotype, behaviour and molecular cues controlling 
haematopoietic progenitors and their differentiation pathways have long been of interest to 




the scientific community. It is hoped that a greater understanding of haematopoiesis will 
translate to more effective therapies for humans.  
 
Figure 1-3. A schema demonstrating the onset of primitive and definitive haematopoiesis in 
human pre-natal development including anatomical sites. Reproduced with permission from 
Macmillan Publishers Ltd (Wang and Wagers91). 
1.3.1 Primitive Haematopoiesis  
Primitive haematopoiesis occurs extra-embryonically exclusively in the yolk sac between days 
17 and 40 of human gestation92, 93. Primitive haematopoiesis is restricted to the production of 
the erythrocyte, megaokaryocyte and macrophage lineages94, 95 . As erythropoiesis refers to 
the specialised production of erythrocytes, primitive haematopoiesis is often termed primitive 
erythropoiesis. Primitive erythroid colony forming cells, the erythro-myeloid precursors 
responsible for primitive haematopoiesis, were first isolated from the murine yolk sac three 
decades ago96. At the time of their emergence, these precursors are the only such precursors 
present in the developing concepti94. Primitive haematopoiesis is quickly succeeded by 
definitive haematopoiesis which marks the beginning of life-long production of all lineages of 
haematopoietic cells97, 98.  
Classical interpretation of yolk sac blood island development stems predominantly from 
studies of chick embryos. Blood islands are generally considered to consist a cluster of primitive 
erythroblasts (which go on to mature in the circulation) surrounded by a covering of flattened, 
spindle-shaped ECs99, 100.  




Following a substantive review of the literature, Ferkowizc et al.101 introduced a novel 
interpretation of blood island development. This is based on the observation that whilst bi-
potential haemangioblasts are present at the primitive streak stage, they are committed to an 
erythroid lineage rapidly after their emergence102-104, meaning that endothelial and 
haematopoietic precursors are present prior to the initiation of yolk sac development101. These 
authors propose that haemangioblast-derived erythroid cells form a single band similar to a 
unique “blood island” in the proximal murine yolk sac by E7.75. This single band is later 
subdivided into numerous blood-filled islands by ECs. Whilst validity of this novel concept is 
yet to be proven, little evidence exists as to how primitive blood islands are formed. 
Conversely, haematopoietic cells within the late-stage yolk sac have been demonstrated to 
derive directly from differentiated ECs. These flattened ECs lining the yolk sac capillaries have 
been demonstrated to produce definitive CD41+ haematopoietic cells at the onset of definitive 
haematopoiesis in the murine yolk sac at E8.25102.  
1.3.2 Definitive Haematopoiesis  
Whilst primitive haematopoiesis occurs exclusively in the yolk sac blood islands101, 105, there is 
evidence for definitive haematopoiesis to occur in the placenta106-111, late-stage yolk sac112, 113, 
the aorta-gonad-mesonephros (AGM) region114-116 and embryonic  arteries117.  
Definitive haematopoiesis consists of two waves with the first occurring in the late-stage yolk 
sac following primitive haematopoiesis105. The erythro-myeloid progenitors of this stage118 lack 
both the ability for self-renewal and restoration of haematopoietic function in irradiated 
murine adults119-121 indicating the absence of HSCs. These erythro-myeloid progenitors are 
proposed to arise at the site of the para-aortic splanchnopleura within the embryo proper, 
seeding the yolk sack, once circulation is established114.  
HSCs responsible for the second wave of definitive haematopoiesis appear later, emerging 
from the intra-embryonic HE lining the dorsal aorta at the AGM region122. These HSCs colonise 
the liver and spleen prior to long-term seeding of the bone marrow which acts as the 
predominate site of post-natal haematopoiesis123, 124. HSCs possess the hallmark 
characteristics of long-term self-renewal and production capability of all haematopoietic 
lineages118.  




1.3.3 Endothelial Origin of Haematopoietic Cells  
Evidence supporting the role of an endothelial precursor to haematopoietic cells, particularly 
the HE and haemangioblasts, is of specific relevance to the present study as the HE lining the 
capillaries of IH is proposed by Itinteang et al.16, 20 to be derived from haemangioblasts. 
Itinteang et al.125 also suggest that primitive haemangioblasts are in fact the in vitro equivalent 
of the HE125. 
In 1917, Sabin126 observed clusters of haemoglobin-filled cells projecting from the endothelial 
wall into the lumen of blood vessels in developing chick embryos, before breaking off and 
entering the circulation - the first observation of the close proximity of endothelial and 
haematopoietic development. Alongside the suggestion that they are a direct precursor to the 
HE, these cells were later named haemangioblasts127 to acknowledge their dual 
haematopoietic and endothelial potential. Sabin’s original observation is now considered to 
indicate a specialised HE rather than strictly bi-potential haemangioblasts. 
That haematopoietic cells have an endothelial origin is now commonly accepted to be 
haemangioblasts, and HE, which are proposed to play a role in both primitive and definitive 
haematopoiesis13. This theory, however, remains controversial with conflicting evidence of the 
exact role and phenotype of a common endothelial-haematopoietic progenitor128-131. Current 
evidence supports the hypothesis that bi-potential haemangioblasts play an essential role in 
primitive haematopoiesis, whilst a HE comprising less than 2% of yolk sac endothelium and is 
present in the AGM region132, is responsible for the generation of multi-potent HSCs in 
definitive erythropoiesis.  Haemogenic activity of the endothelium is supported by more recent 
work demonstrating the expression of EPOR on the vascular endothelium with enhancement 
of proliferation of ECs in response to EPO133.   
During the past decade committed primitive erythropoietic precursors, expressing GATA-1, 
have been demonstrated within the yolk sac. These GATA-1+ cells have been reported to arise 
from a subset of mesodermal cells expressing endothelial markers (CD31+/VEGFR-2+/VE-
cadherin+/TIE2+/ CD34+/endoglin+) at gastrulation134. Similarly VE-cadherin+/CD45-/Ter119-5 
and VE-cadherin+/VEGFR-2+135 ECs isolated from the concepti and yolk sac, respectively, 
demonstrate capacity for haematopoietic production. 





The identification and investigation of the processes involved in haematopoiesis from ECs 
involve the identification of specific markers including cluster of differentiation (CD) molecules 
and haematopoietic transcription factors. CD molecules are cell surface proteins typically 
involved in cell signalling by acting as receptors or ligands, with a few acting instead as cell 
adhesion molecules136. Markers relevant to this study and the preceding literature are 
introduced below. 
1.1.1.1.1 Haematopoietic Markers 
The earliest haemogenic activity can be identified by detection using the primitive transcription 
factors, Tal-1, GATA-1, and GATA-2. CD41103, 137  and CD43138 signal haematopoietic 
commitment whilst CD41106 and RUNX-1139 have also been used identify HSCs. CD45 marks 
differentiated cells of all definitive haematopoietic lineages140, and distinguishes such cells 
from the primitive erythroid lineage137.  
1.1.1.1.2 Wagner’s Endothelial Markers 
The hierarchy of endothelial development is less complex than haematopoietic differentiation 
patterns, as the expression of a single or multiple EC markers identifies a cell as of endothelial 
origin134. Wagner141 defined the endothelium by its expression of the markers, CD31, VEGFR-
2 and TIE-2, along with capability of acetylated-LDL uptake. Wagner’s markers have varied roles 
associated with endothelial function. CD31 is a leukocyte trans-endothelial migration factor142 
whilst VEGFR-2 is a subtype of VEGFR143. TIE-2 is involved in angiopoiesis, acting as a kinase 
receptor for angiopoietin144, 145. CD34 is also commonly used in the study of haematopoiesis 
and visualisation of small vessel vascular endothelium as it is a glycoprotein associated with 
early haematopoietic and vascular tissue146.  
  





Despite the proposed common haematopoietic-endothelial precursor 80 years earlier126, 127, it 
was not until the close of the 21st century that undisputed evidence of haemangioblasts first 
arose5, 147 . Earlier reports were limited to the demonstration of markers, such as those 
introduced above, common to both haematopoietic precursors and the endothelial lineage or 
the necessity of endothelial markers in haematopoietic development. Endothelial markers, 
CD34148, 149  and VEGFR-2150, were both demonstrated on haematopoietic progenitors with 
VEGFR-2 expression also noted in the haematopoietic sites of the yolk sac blood islands151 and 
the developing allantois151, 152 . In 1996, it was suggested that the two cell types derived from 
haemangioblasts were angioblasts (an endothelial precursor) and HSCs153. 
A relationship between haematopoietic and endothelial development is highlighted by 
embryonic fatality resulting from failed blood island formation in a homozygous knockout 
mouse, null for the endothelial ligand receptor, VEGFR-2154.  Cells lacking VEGFR-2 in a non-
fatal model are incapable of endothelial or haematopoietic production and fail to migrate from 
the primitive streak to the yolk sac blood islands155. Such evidence suggests that whilst VEGFR-
2 signalling may not be essential in the differentiation of haemangioblasts it is critical for 
haemangioblast migration and expansion156.   
In 1997, Eichmann et al.157 isolated VEGFR-2+ cells from chicken embryos and demonstrated 
their differentiation potential for both endothelial and haematopoietic lineages. The authors 
proposed that the differentiation was determined by activation of VEGFR-2. The VEGFR-2+ 
population was differentiated down the endothelial lineage in the presence of VEGF whilst its 
absence promoted haematopoietic differentiation. The authors proposed that such evidence 
demonstrated that a bi-potential precursor was present at the onset of haematopoiesis 
negating the alternate hypothesis of necessity of an endothelial microenvironment157.  
In 1997, Kennedy et al.158 isolated blast-colony forming cells (BL-CFCs) from embryoid bodies 
cultured from differentiated embryonic stem cells (ESCs) (Fig. 1.4). This precursor represented 
a transient in vivo population, present before the production of primitive and other lineage 
restricted precursors, and possessed the ability to produce both primitive and definitive 
haematopoietic progeny. When cultured in VEGF, c-kit ligand, and conditioned (endothelial) 
media, these BL-CFC formed immature colonies expressing both haematopoietic (Tal-1 and 
GATA-1) and endothelial (VEGFR-2 and CD34) markers158.  






Figure 1-4. Demonstration of the morphological distinction between blast-colony forming cells 
(BL–CFC) and embryoid body (EB) isolated from hESC culture. Reproduced by permission from 
Macmillan Publishers Ltd (Kennedy et al,158). 
In the following year, the group demonstrated BL-CFCs could undergo not only primitive and 
definitive haematopoiesis but also endothelial differentiation in vitro when cultured in liquid 
medium containing both haematopoietic and endothelial growth factors. BL-CFCs were thus 
hypothesised as the in vitro equivalent of haemangioblasts147. In the same year, Nishikawa et 
al.159 reported the production of CD45+ haematopoietic cells from VEGFR-2+ cells which also 
expressed VE-cadherin, an exclusive endothelial marker. This study used murine ESCs from 
which a VEGFR-2+/VE-cadherin+ population was isolated. Cells of the same phenotype were 
also isolated from the murine yolk sac and demonstrated to have similar differentiation 
potential. Nishikawa et al.159 demonstrated that 2D culture was sufficient for haematopoietic 
production, with the production of embryoid bodies or feeder cells not being required. These 
authors proposed that the VEGFR-2+/VE-cadherin+ population represents the diverging point 
of haematopoietic and endothelial lineages from a common precursor159. 
Subsequent to this first demonstration, multiple groups have isolated haemangioblasts/BL-
CFCs and demonstrated their production capacity. Reports of CD31+/VEGFR-2+/VE-
cadherin+/CD45- cells derived from hESC culture160 and VEGFR-2+ haemangioblasts104, 161, both 
capable of haematopoietic and endothelial production from single cell culture, further 
emphasised these findings. More specifically, brachyury+/VEGFR-2+ haemangioblasts have 
been demonstrated to produce primitive erythroid cells, consistent with those produced in 
yolk sac primitive haematopoiesis162. Fujimoto163 further characterised haemangioblast 




development, demonstrating that in VEGFR-2+ haemangioblasts, the expression of GATA-1 
marked commitment to erythroid and macrophage progenitor differentiation pathways. The 
remaining GATA-1-/VEGFR-2+ population, VE-cadherin+ ECs developed and went on to produce 
multi-lineage definitive HSCs163.  
In 2007, Kennedy et al.164 used extended culture to characterise distinct populations of 
haemangioblasts lacking β-globin which produced different haematopoietic lineage progeny. 
Whilst a lack of β-globin demonstrated that both populations correlated with primitive 
haematopoiesis, smaller colonies gave rise only to primitive erythrocytes whilst larger colonies 
expressed colony stimulating factor receptor 1 (C-FMS) indicating additional ability to produce 
macrophages. Also reported was the production of megakaryocytes, with the ability to produce 
thrombocytes, from haemangioblasts165.  
Early embryoid body culture from hESCs indicated that BL-CFCs were present prior to primitive 
erythroid cells164 with evidence demonstrating, in the mouse, that the presence of the 
haemangioblasts marked the first instance of human haematopoietic commitment164. The 
haemangioblast population in vivo peaked at the neural plate stage of the primitive steak104 
which correlate with day 15 of embryological development166. 
More recently the direct contribution of haemangioblasts to primitive haematopoiesis has 
been better elucidated by the use of a green fluorescent protein (GFP) reporter gene 
technique167. Teixeria et al.167 identified a haemangioblast specific enhancer within the cis-
regulatory region of the Cerebus gene. The incorporation of the GFP gene down-stream of this 
enhancer within the chick genome resulted in GFP expression in haemangioblast cells167. GFP 
labelling here enabled live in vivo imaging of the development, migration, and subsequent 
differentiation of haemangioblasts in chick development. These authors tracked GFP 
expression at the primitive streak with subsequent migration through the primitive streak and 
the formation of the yolk sac blood islands, concluding that the precursor does develop at the 
primitive streak and migrate to its site of production. GFP was later observed in differentiated 
haematopoietic and endothelial populations within the extra-embryonic yolk sac, 
demonstrating their derivation from the early haemangioblast precursor167.  




1.1.1.1.3 Modulation of Haemangioblasts In Vitro 
Identification of haemangioblasts/BL-CFCs and their capacity for dual haematopoietic and 
endothelial differentiation, have prompted investigation into the determinants for their 
differentiation potential.  
Early studies using embryoid body culture, reported that VEGF was essential in BL-CFC 
formation158, 164. However, a more recent report demonstrates that neither VEGF, nor stem 
cell factor (SCF), nor insulin-like growth factor 1 (IGF-1), nor epidermal growth factor alone is 
sufficient to produce BL-CFCs in culture168. FGF-2 is the most commonly reported prerequisite 
of haemangioblast development161, 168, 169 with the angiogenic cytokine, endoglin170, being 
necessary  for subsequent haematopoietic production from haemangioblasts171.  
Interestingly, interleukin-3 (IL-3) has also been demonstrated in BL-CFC assay to enhance both 
cell numbers and capacity through the action of the JAK-STAT pathway172. The involvement of 
the RAS has been suggested by the demonstration of the expression of ACE, a component of 
the RAS, on haemangioblasts79.   
1.1.1.1.4 Are Haemangioblasts Strictly Bi-potential?  
With BL-CFCs commonly reported as the in vitro equivalent of the bi-potential 
haemangioblasts, there remains speculation as to whether their capacity is strictly limited to 
the haematopoietic and endothelial lineages. In 2003, Ema et al.173 reported in vitro 
development of smooth muscle cells (SMCs) from BL-CFCs. VEGFR-2 is commonly used as a 
haemangioblast marker, however, it is expressed on a variety of mesodermal precursors174. An 
early mesenchymal VEGFR-2+ population derived from ESCs has been shown in vitro to possess 
the capacity for endothelial, cardiomyocytic, mural and both primitive and definitive 
haematopoietic differentiation175.   
A new precursor, the mesenchymangioblasts, has been characterised following hESC 
differentiation co-culture with OP9 cells168, which may explain the variation in the report of BL-
CFC cells. After two days of hESC differentiation culture, compact spheroid structures 
consisting of densely packed cells are observed. Another 24 hours later, more disperse 
structures with a morphology similar to that of the previously reported BL-CFCs are observed. 
Subsequent culture revealed that both of these mesoderm-derived structures are capable of 
endothelial differentiation with later development of dispersed structures producing CD43+ 




haematopoietic cells with few mesenchymal cells. The compact spheroid structures of densely 
packed cells were demonstrated to possess the additional capacity of MSC production and 
were consequently named mesenchymoangioblasts. Thus, this report highlighting two distinct 
precursors, both with endothelial potential, may explain earlier production of non-
haematopoietic-endothelial mesenchymal lineage cells from supposed haemangioblast 
precursors.    
1.3.3.3 Haemogenic Endothelium  
Around the same time when the role of haemangioblasts in primitive haematopoiesis was 
emerging, evidence was accumulating regarding the production of definitive haematopoietic 
cells from a morphologically endothelial population lining the dorsal aorta176, 177. The lining of 
the dorsal aorta expresses VEGFR-2, marking it phenotypically endothelial. Discrete areas of 
this region, however, form VEGFR-2-/CD45+ haematopoietic clusters. This stimulated further 
investigation of the potential endothelial origin of these CD45+ cells. Labelling of this dorsal 
aorta endothelial population with Dil-conjugated low density lipoproteins (Dil-LDL) has 
demonstrated that such cells go on to produce definitive haematopoietic cells176, 177 which 
display an adult haemoglobin chain arrangement176. These cells arise at the pre-liver stage ad 
are proposed to be released into the circulation with the ability to colonise later 
haematopoietic sites such as the foetal liver176.  
Multi-potential HSCs, the precursors to the adult haematopoietic system, arise from a HE lining 
the dorsal aorta of the AGM region178. The recently termed endothelial-haematopoietic 
transition14 describes the process by which  HSCs arise from single ECs which bend to enter the 
sub-aortic space ,before acquiring a haematopoietic phenotype and detaching to enter the 
circulation179. Fate tracing confirms that HSCs arise directly from ECs, however, it is proposed 
that the underlying mesoderm provides an essential niche for their development180.  
Lancrin et al.104 identified a TIE2+/c-Kit+/CD41- HE as the intermediate between the 
brachyury+/VEGFR-2+ haemangioblasts of the primitive streak and haematopoietic precursor 
cells present in the yolk sac94. Whilst the transient TIE2+/c-Kit+/CD41- HE population was 
identified in both the murine yolk sac of gastrulating embryos and the AGM region, it remains 
unlikely that such a simplistic model would encapsulate the entirety of haematopoietic 
development.  




Programmed physiology of the HE is characterised by an initial endothelial morphology 
including the expression of VE-cadherin allowing tight junction formation and the ability to take 
up acetylated-LDL prior to the expression of CD45140. Eilken et al.140, using continuous live cell 
imaging, demonstrate that cells transition toward CD45+/c-Kit+ haematopoietic cells following 
the down-regulation of VE-cadherin and subsequent loss of tight junctions.  
Figure 1.5 demonstrates the expression of both haematopoietic and endothelial markers on 
two haematopoietic precursor populations derived of hESC culture. Eilken et al.140 
demonstrate a population which transitions from an adherent endothelial population through 
to CD45+ haematopoietic cells. Lancrin et al.169 demonstrate a haemangioblast population 
which transitions from tight endothelial colonies through to haematopoietic blast colonies.  
 
 
Figure 1-5. Relative expression of endothelial and haematopoietic molecular markers on two 
hESC haematopoietic precursor populations. Reproduced with permission from Elsevier 
(Dieterlen-Lievre and Jaffredo181).  
Nakajima-Takagi et al.182 used CD43 expression in iPSC culture to characterise three phases of 
haematopoietic progenitor cells. An initial CD34+/CD43-/CD45- EC population with 
haematopoietic potential progresses to a final CD34+/CD43+/CD45+ stage representing the HSC 
population with an intermediate CD34+/CD43+/CD45- population termed the pre-HSC cell182, 
183. Nakajima-Takagi et al.182 further used this model to investigate the roles and importance 




of various haematopoietic genes aiming to identify possible targets to enhance haematopoietic 
production iPSC culture. In this HE model SOX-17 over-expression resulted in failed 
haematopoietic development instead of prolonging the endothelial stage. SOX-17 is 
determined an essential regulator of HE expansion. This study also determines RUNX-1, a 
transcription factor and HSC marker139, as a down-stream target of SOX-17 signalling182. The 
absence of RUNX-1 elsewhere has been demonstrated to result in failed HSC production169, 184. 
However, its distinct role remains unclear as studies offer conflicting evidence as to whether it 
functions in the establishment of the HE184 or the subsequent development of HSCs169. 
1.3.3.4 Common Origin of Haemangioblasts and Haemogenic Endothelium  
As this field evolves distinction between primitive and definitive precursors remains elusive. 
Potential overlaps have been suggested for the roles of both haemangioblasts and HE. Cell 
tracing has demonstrated the ability of yolk sac precursors to contribute to both primitive and 
definitive adult haematopoiesis185 and it has also been observed that immune lineage 
progenitors arise prior to multi-potential HSCs186. Similarly Yamane et al.187 have isolated a 
CD45-/CD93-/CD41+ precursor population from both concepti and yolk sac which produced 
both primitive erythroid and definitive lympho-myeloid cells in vitro, with CD93 up-regulation 
associated with definitive commitment. This bi-potentiality was not observed in vivo as 
demonstrated by primitive erythroid cells arising uniquely in the yolk sac despite the 
progenitors being present in the embryo proper suggesting that differences may exist between 
in vivo and in vitro physiology. Another study observed that a single blast colony from embryoid 
body culture could be directed down both primitive and definitive lineages following addition 
of appropriate cytokines158. It also remains to be determined if identical bi-potential precursors 
isolated from distinct anatomical sites are developed in situ or solely in the yolk sac with some 
later infiltrating the embryo proper after circulation is established. As demonstrated by the 
driving of different differentiation pathways with administration of cytokines, it is possible that 
these precursors have identical potentiality with their differentiation driven by unique 
microenvironments.  
Whilst reports of HE activity focus generally on the production of HSCs, Lancrin et al.169 suggest 
that both primitive and definitive haematopoietic cells can arise from a HE with induction of 
definitive production solely dependent on RUNX-1 expression. 




The authors of the 1998 seminal publication on BL-CFCs as in vitro equivalent to 
haemangioblasts147 recently published a very robust study detailing the development of 
haematopoietic precursors in a sophisticated hPSC model of haematopoiesis14. This model was 
used to produce both a HE precursor (HEP) and the primitive precursor haemangioblasts. Choi 
et al.14 suggest that identification of the HEP is key to in vitro generation of HSCs. They 
determine that whilst haemangioblast precursors arise from the posterior primitive plate 
mesoderm after three days of differentiation culture, HEPs of the definitive haematopoietic 
system arise later and represent a distinct lineage14.  
Figure 1.6 demonstrates the hierarchy of endothelial and haematopoietic development as 
detailed by Choi et al.14. The key finding of this work is the definitive demonstration that 
primitive haemangioblast pre-cursors and definitive HE arise from distinct stages of 
mesodermal commitment (Fig. 1.6). The first stage of angio-haematopoietic development 
observed by Choi et al. in hPSC co-culture with OP9 cells was at day three of culture with a 
haemangioblast/BL-CFC stage arising from primitive posterior mesoderm with the phenotype 
EMHlin-/APLNR+/PDGFRα+ (where EMHlin represents mesenchymal, endothelial and 
haematopoietic markers CD31/VE-cadherin/CD73/CD105/CD43/CD45) (Fig. 1.6). This 
haemangioblast precursor is proposed by the authors as equivalent to the HE of the early yolk 
sac. BL-CFCs were observed to form endothelial cores with intracellular as opposed to 
membranous VE-cadherin, demarcating them as distinct from a HE morphology (Fig. 1.7). Such 
BL-CFCs produced predominantly primitive erythroid cells but retained definitive capacity in 
the presence of appropriate haematopoietic factors.  
 





Figure 1-6. The hierarchal development of endothelial and haematopoietic precursors from 
primitive mesoderm. Reproduced with permission from Cell Reports (Choi et al14). 
 
Figure 1-7. Day 3 endothelial core structures and day 12 mature haemangioblast colonies 
arising from clonogenic culture with apelin and FGF-2. Reproduced with permission from Cell 
Reports (Choi et al14). 
The primitive mesoderm responsible for BL-CFC production then proceeds through more 
complex stages of mesodermal precursors (Fig. 1.6) with KDR (VEGFR-2) up-regulation and 
platelet-derived growth factor receptor-α (PDGFR-α) down-regulation resulting in a 
mesodermal phenotype of EMHlin-/KDRbright/APLNR+/PDGFRαlow termed by Choi et al.14 as the 
haematovascular mesodermal precursors (HVMP). The HVMP represents a mesodermal 
precursor arising at the post primitive streak stage of differentiation which is distinct from the 
primitive haemangioblasts. Three distinct precursor populations were observed to derive from 
the HVMP stage, briefly the HE precursors (HEP), the non-HE precursor (non-HEP) and the 
angiogenic haematopoietic progenitor (AHP) (Fig. 1.6). The key finding being that 
haemangioblasts, whilst retaining some inducible definitive capacity, arise from mesoderm 




earlier than definitive counter parts and likely produce haematopoietic progeny through an 
endothelial core stage rather than a morphologically endothelial stage14. 
1.3.4 In Vitro Haematopoietic Models  
In vitro models used for the study of haematopoiesis have utilised hESCs in co-culture with 
feeder cells (typically OP9 cells)5 or more recently iPSCs as described by Yamanaka7, who was 
later awarded a Nobel Prize for this work188. It is worth noting that the use of cord blood cells 
for the derivation of HSCs and haematopoietic progenitors and the use of feeder free systems 
have also been employed for the study of haematopoiesis159. 
1.3.4.1 Erythroid Precursor Culture 
In 2000, CD34+ HSCs and erythroid precursors were successfully cultured in vitro to achieve a 
population of nucleated erythroid precursor cells which underwent successful terminal 
differentiation to functional erythrocytes in vivo in a diabetic, immuno-deficient murine 
model6, with the application of numerous cytokines, such as SCF, Flt-3 ligand, EPO, IL-3, IL-6, 
and granulocyte colony stimulating factor (G-CSF) to drive the expansion of various 
haematopoietic lines6, 189.  
In vivo regulation of erythrocyte enucleation remains elusive with the suggestion of 
macrophage involvement somewhat controversial. However, it remains a crucial step in 
achieving functional erythrocytes for human transfusion. The transfusion of terminally 
differentiated erythrocytes is desirable over that of erythroid precursors due to variability in in 
vivo differentiation and the proposed lesser tumourigencitiy of enucleated product due to its 
lack of genetic material190. The majority of in vitro culture of these cells requires the use of 
feeder populations or “co-culture” techniques, ultimately this is another hindrance to the 
clinical application of ex vivo tissue.  
Glucocorticoids have been reported to both enhance the proliferation of erythroid precursors 
as well as delaying terminal differentiation191, whilst the application of their inhibitors has 
conversely been noted to expedite the process of enucleation, in the absence of feeder cells192 
as do insulin and heparin9. A protocol developed by Miharada et al.192, does not require the 
use of feeder cells. However, it requires multiple passaging of cells and the application of 
numerous exogenous cytokines. In the first passage the application of VEGF and insulin-like 
growth factor II (IGF-II) is noted to promote proliferation of erythroid precursors, with the 




autonomous enucleation of these cells highlighting the protocol as a potential ground breaker 
in establishing economic and efficient en masse ex vivo erythropoiesis192, 193.  
A limitation to the studies has been the difficulty in establishing erythroid precursor cell lines 
due to the instability in telomere length following multiple passages194. However, this is not a 
consideration in the establishment of ESC lines which are less vulnerable to genetic changes190. 
1.3.4.2 Embryonic Stem Cell Culture 
ESCs from human, primate and murine origin have been used to generate haematopoietic 
cells, typically with the use of OP9 feeder cells195 which are notoriously high maintenance and 
are sensitive to changes in culture conditions4. Also this route of erythrocyte production is 
relatively inefficient due to the number of differentiation stages that need to be achieved prior 
to terminal differentiation. Murine studies using OP9 co-culture allows both primitive and 
definitive erythrocyte production and differentiation159, 196. Haematopoietic differentiation has 
also been achieved from both hESC and iPSC lines with the application of numerous exogenous 
factors in feeder-free culture197-201. 
Success in the generation of erythroid precursors from ESCs was achieved by Hiroyama et al.202 
in which they were in the development of five haematopoietic cell lines; and mouse ESC-
derived erythroid progenitor (MEDEP) cell lines, three of which exhibited erythroid 
characteristics202. Cells were transfused into an anaemic mouse model following in vitro 
differentiation to erythroid precursor state (with some erythrocyte terminal differentiation) 
and noted to undergo brief expansion with subsequent differentiation. Whilst this protocol is 
a great advancement, limitations remain in the differentiation regimes required for murine ESC 
differ from hESC culture202.  
In vitro demonstration of haematopoietic differentiation of hESCs through primitive and 
definitive waves of haematopoiesis parallels the natural development of the yolk sac 
physiology138, 203. The presence of erythro-megakaryocytic cells (CD235a+/CD41+/CD45-) 
before the multi-potent lympho-haematopoietic progenitors (VEGFR-2+/VE-cadherin+/GATA-
2+/GATA-3+/RUNX1+/CD41-/CD235a-) has been argued to mirror the developmental biology of 
the yolk sac and therefore demonstrating that an inherent physiological programme observed 
in vitro, consistent with in vivo ontogeny138, 204.  




1.3.4.3 Induced Pluripotent Stem Cell Culture 
In 2012, Shinya Yamanaka was awarded the Nobel Prize for demonstrating induction of the 
expression of four primitive genes revert adult fibroblasts to an ESC-like pluripotent state, 
naming these cells iPSCs7. iPSCs are characteristically similar to hESC205, 206 and thus provide a 
useful tool in the ethical and efficient establishment of en masse human specific in vitro 
erythropoiesis.  
Ex vivo erythropoiesis from iPSCs in co-culture with OP9 cells is said to be as efficient as hESC 
culture10. Such culture produces CD235a+/CD45- erythrocytes which express γ- and ε-globins 
with very little β-globin expression10, 207. Kobari et al.9 demonstrate that the haemoglobin 
expression pattern was consistent in both a normal and pathological sickle cell disease in vitro 
differentiation protocol9. As in previous hESC studies, Kobari et al.9 infused nucleated 
erythroblast colonies into immunocompromised mice and observed an in vivo foetal to adult 
haemoglobin switch. Since these early studies numerous groups have again demonstrated the 
haematopoietic potential of iPSCs as reviewed by Daley 2014208.  
In 2013, Hirose et al.12 demonstrated that induction of c-MYC and BCL-XL expression in 
erythroblasts, “immortalised” these cells, allowing indefinite self-replication of glycophorin A+ 
erythrocytes. Subsequent down regulation of these induced genes, resulted in terminal 
maturation. This highlighted a potential mechanism by which a precursor population may be 
established to achieve optimal numbers for future transfusions12. 
Most recently Yang et al.11 reported success in the development of a haemo-endothelial 
precursor from differentiated iPSCs11. These multi-potential cells were capable of producing 
CD144+ ECs, CD235a+ erythrocytes and lymphoid lineage B lymphocytes. Erythroblasts 
achieved in this culture co-expressed both foetal and adult haemoglobin, however, was also 
noted to be observed similarly in the culture of cord blood derived erythroblasts. A specific 
erythro-myeloid progenitor was successfully isolated from culture.  
1.3.5 The JAK-STAT Signalling Pathway  
Signal transducers and activators of transcription (STAT) are a family of seven proteins acting 
as intra-cellular messengers with a variety of roles including erythropoiesis and blood 
ontogeny209-211, haematopoietic precursor expansion212-215, and maintenance of stem cell 
pluripotency216, 217. Latent STATs reside within the cytosol and are activated when ligand 




binding at cognate cell surface receptors induces phosphorylation of tyrosine molecules within 
the STAT SH2 domain (Fig. 1.8). Tyrosine phosphorylation is generally modulated by Janus 
Kinase (JAK) molecules hence the term JAK-STAT pathway218 (Fig. 1.8). Once phosphorylated, 
STAT proteins dimerise and translocate to the nucleus to modulate gene expression211, 219-221 
acting as transcription factors219, 220 by binding to specific DNA promoter sequences222 (Fig. 
1.8).  
 
Figure 1-8 Activation and down-stream signalling of the JAK-STAT pathway. Reproduced with 
permission from Macmillan Publishers Ltd (Levy and Darnell223). 
The JAK-STAT pathway can be activated by more than 35 ligands219 meaning that its functions 
encapsulate a wide range of biological roles including IL-signalling224-227, haematopoiesis 209, 228, 
229, and its activation is tightly regulated230. Constitutive activation and signalling of STAT family 
proteins induce the inappropriate expression of cell cycle progression genes suggested to 
promote oncogenesis through anti-apoptotic effects231. Activation of STAT family members has 
been widely investigated and reported in many cancer types and the therapeutic potential 
STAT inhibitors has also been explored with some success in oncology232.  
The RAS has been implicated in inducing JAK-STAT signalling and has been demonstrated to 
mediate ATII-induced gene transcription. In multiple studies, both activation of JAK-2233-237 and 
phosphorylation of each of the seven members of the STAT family in cardiac cells238-243 has 
been demonstrated by application of ATII. JAK-STAT pathway is now recognised as a potential 
target for clinical and molecular studies in blood pressure regulation244. Its implication of STATs 
in tumourigenesis it yet to be established.  




The following sections outline the various roles of STAT1, STAT3 and STAT5 in IH, forming the 
basis of this present study.  
1.3.5.1 STAT1  
STAT1 is a pleiotropic protein with the ability to induce both activation of transcription and 
suppression of gene expression245 with a total of 1,441 down-stream genetic targets246. 
Activators of STAT1 include the interferon (IFN) family245, IL-6247, and SCF248. STAT1 is 
predominantly active in defence against infection related to IFN signalling246. In response to 
type I (IFN-α and IFN-β) and type II (IFN-γ) IFN signalling, STAT1 is activated by JAK-mediated 
tyrosine phosphorylation249. Tyrosine phosphorylation enables STAT1 homo-dimers to form 
which translocate to the nucleus219, 250-252. Enhancement of activity and full transcription 
capability requires phosphorylation of the STAT1 serine residue (Ser727) which occurs in 
addition to, and independent of, JAK-mediated tyrosine phosphorylation253 
1.1.1.1.5 STAT1 and the Interferons  
The most widely reported activators of pSTAT1 are type I and type II IFN245.  
IFN-α is a cytokine secreted mainly by dendritic cells in the innate immune response against 
viral infection254. Within the context of haematopoiesis, IFN-α signalling has been reported to 
stimulate dormant HSCs entry into the cell cycle dependent on the STAT1 signalling pathway212. 
Whilst IFN regulatory factor 2, a repressor of IFN-α transcriptional activity, preserves HSC 
inactivity255.  
IFN-γ, the only member of the type II IFN family, is predominantly secreted by macrophages 
and activated T cells256. Initial reports of IFN-γ signalling in haematopoiesis labelled it as a 
haematopoietic repressor based on in vitro inhibition of colony formation and differentiation 
alongside HSC apoptosis257, 258. More recently, physiologically advanced models of infection, 
the secretion of IFN-γ is proposed to promote expansion of HSCs213, 214 and myeloid 
progenitors215, 259-261 with some groups demonstrating that this dependent on STAT1 
signalling213, 260. Elsewhere IFN-γ induces IL-6 (another known STAT1 activator) secretion from 
MSCs within the bone marrow has been reported to induce expansion of myeloid 
progenitors262. Exhaustion and consequent apoptosis of HSCs can result from excessive 
signalling of either IFN-α212, 255, 263 or IFN-γ258, 264.  




Vishvanath265 demonstrated the modulation of the JAK-STAT signalling pathway in IHMSCs by 
VEGF and IFN-α2b. It was noted that whilst VEGF application did not affect STAT1 activity, the 
application of IFN-α2b application to IHMSCs in culture increased both the phosphorylation 
status of STAT1 and promoted its nuclear translocation indicating the STAT1 signalling in IH 
may be related to the clinically observed IFN induced involution40.  
1.3.5.2 STAT3 
Initial reports of STAT3 highlighted its role as a transcription factor in the signalling of acute 
phase response in inflammation. Accordingly STAT3 was named acute phase response factor 
and has been studied widely in relation to tumourigenesis266.   
Functions of STAT3 signalling include IFN signalling, inflammatory and immune response, 
invasion, angiogenesis and cell cycle267. Down-stream target genes of STAT3 signalling include 
proliferation genes such as cyclin D1268-270, anti-apoptotic genes, BCL-XL271, 272 and Mcl-1272, 
and VEGF273 which contribute to angiogenesis and tumour invasion267, 274.  
Vishvanath265 has previously demonstrated the expression pattern of STAT3 within IH. 
Particularly of note is the nuclear co-localisation of STAT3 with proliferation marker, 
proliferating cell nuclear antigen (PCNA) within proliferating IH sections. However, it is noted 
that PCNA is not co-expressed in all cells expressing STAT3 and the phosphorylation state of 
STAT3 was not investigated. In IHMSC culture, the activation and nuclear translocation of 
STAT3 has been observed to be enhanced following the application of IFN-α2b but not VEGF265.  
In oncology, deregulation of signalling pathway components or constitutive STAT3 activation 
contributes to cancer cell proliferation267, 275, 276. STAT3 has been demonstrated as 
constitutively active in many human cancers276-278. However, as more is revealed about the 
complexity of signalling through the STAT3 pathway, the consequence of inappropriate STAT3 
activation cannot be easily interpreted. It is believed that effects of STAT3 signalling may differ 
dependent on other signalling events and factors within the microenvironment, e.g., the loss 
of down-stream regulators such as the suppressor of cytokine signalling (SOCS) family 
members267.  
Concurrent signalling of STAT3 and STAT5 has also been reported279, 280. In a breast cancer 
model, the combined signalling of STAT3 and STAT5 found in 40% of cases, has been correlated 
with lower-grade, more differentiated tumours and is associated with better clinical 




outcomes279. Theories for this improved prognosis include differing cellular origins of the 
tumour cells with both STAT3 and STAT5 activation compared with STAT3 activation alone280. 
Cells displaying nuclear localisation of both pSTAT3 and pSTAT5 have been demonstrated to 
proliferate more slowly, meaning that they may be more susceptible to cell death induced by 
chemotherapeutic agents267.  
1.1.1.1.6 STAT 3 and Stem Cell Maintenance  
The maintenance of hESCs in a pluripotent state is reported to be dependent on the signalling 
of leukaemia inhibitory factor (LIF)281-283 a member of the IL-6 family284. LIF signals through a 
receptor complex which includes the component gp130283, 285, 286. Ligand binding to the 
receptor results in the JAK-mediated phosphorylation of both the receptor associated gp130 
molecule and STAT3284, 287, 288. Elucidation of this pathway and further investigation has 
revealed STAT3 signalling as a critical component of LIF-mediated stem cell maintenance217, 287, 
289. It has been demonstrated that STAT3 signalling regulates the Nanog-Oct4 pathway, a key 
mediator of pluripotent cell maintenance, through binding to distal enhancers in both the 
Nanog and Oct-4 genes once activated216.  
In the cancer context, an equivalent role for STAT3 in the maintenance of cancer stem cell 
(CSC) pluripotency has also been suggested290, 291. In glioblastoma the expression of activated 
STAT3 was observed to correlate with the expression of markers of neural stem cell 
multipotency whilst genetic mutation of the STAT3 revealed inhibition of stem cell 
proliferation290. In a murine model of prostate cancer, the expression of activated STAT3 was 
observed to correlate with the elevated expression of CSC markers291. Both inhibition of IL-6 
signalling and STAT3 activation within this model results in decreased tumour mass 
proliferation291.  
Despite a wide body of convincing evidence that STAT3 is the key mediator of LIF signalling and 
maintenance of stem cell pluripotency, Yamanaka284 suggests these observations may not hold 
true for human biology. This is based primarily on the in vitro demonstration of LIF to promote 
hESC self-renewal292 and the low expression levels of components of the LIF/STAT3 pathway 
within these cells293. Yamanaka284 has also proposed that a mechanism independent of 
LIF/STAT3 signalling functions to maintain hESC pluripotency.  





STAT5 is widely reported as a down-stream messenger of EPOR, playing a role in both primitive 
and definitive erythropoiesis294. STAT5 activation of EPOR promotes down-stream 
transcription of anti-apoptotic genes including BCL-XL295-297, consequently promoting 
proliferation and survival224, 298-300. In IHMSC culture STAT5 was activated and underwent 
increased nuclear translocation following the application of VEGF265. VEGF application to IH 
explant culture is noted to stimulate significant capillary-like sprouting from the explant 
tissue265. These two observations may indicate that STAT5 may play a role in the signalling of 
VEGF within IH.  The application of IFN-α2b to the culture of IHMSC was observed to induce 
phosphorylation and enhanced nuclear translocation of STAT5 as observed for STAT1 and 
STAT3265.  
STAT5 activation is sufficient to ameliorate a lack of either JAK-2 or EPOR signalling and restore 
functional erythropoiesis228 whilst its over-expression or that of BCL-XL results in replication of 
in vitro behaviour that corresponds with polycythaemia vera301, as in JAK2 mutation-induced 
clinical cases302. JAK2 is the only JAK molecule associated with the EPOR and therefore a unique 
mediator of EPO signalling303. However, it seems that JAK2 up-regulation may hinder cellular 
differentiation through non-STAT pathways303, 304. 
In homozygous null mice the absence of STAT5 is embryonically fatal with decreased survival 
of early erythroblasts with STAT5 expression levels inversely correlated with the severity of 
anaemia305. In a similar knock-out study Kereyni et al.306 demonstrate that even in fatal 
embryonic cases, STAT5 null animals exhibit erythroid cells at all stages of development. These 
authors propose that the role for STAT5 may be in erythroid cell metabolism rather than 
differentiation. More specifically it is suggested that STAT5 may modulate iron uptake through 
transferrin receptor (TfR) and induce the anti-apoptotic MCL-1 gene306.  The importance of the 
BCL-XL gene and down-stream target of pSTAT5 in the onset of primitive haematopoiesis is 
demonstrated by haemolytic anaemia and splenomegaly in homozygous negative mice307. 
1.3.6  The Role of Short Chain Fatty Acids in Haematopoiesis  
Fatty acids are a group of organic compounds with the functional group, the aliphatic tail. 
Those in which the aliphatic tail consists of 6 or less carbon molecules represent the subgroup 
of short chain fatty acids (SCFAs)308. SCFAs are produced by the colonic fermentation of dietary 




fibre309. They are proposed to promote the health of colonic mucosa309 by inducing G1 cell 
cycle arrest310. They have also been demonstrated to induce differentiation of colonic cancer 
cell lines309, 310.  
Relevant to the present study, the limited efficacy of treatment options available for patients 
suffering from thalassemia and other haemoglobinopathies has long stimulated research 
towards novel therapies, with the ultimate goal to dispense with the current human-to-human 
transfusion therapy. A line of investigation has focused on the role SCFAs play in the induction 
of foetal haemoglobin that has been shown to be beneficial for haemoglobinopathies. SCFAs 
induce γ-globin expression311 and in increased mRNA translation312. Some SCFAs and their 
derivatives, however, inhibit cell proliferation thus limiting their application in the treatment 
of thalassemia313-315. Key findings of such studies and their relationship to primitive 
haematopoiesis are outlined in the following paragraphs.  
In 1975, Leder and Leder316 demonstrated a novel use of the endogenous cytokine, butyric 
acid, to induce erythroid differentiation. In culture of erythroleukaemic cells, butyric acid as an 
effective inducer of erythroid differentiation at one-hundredth the concentration of di-methyl 
sulfoxide (DMSO), the most efficacious known inducer at the time.  The activity of butyric acid 
in this study was unique amongst the tested compounds with reported inactivity of SCFAs of 
other carbon chain lengths and lack of induction by other organic compounds lacking a 
carboxyl group. The erythroid differentiation capacity of butyric acid was supported by in vivo 
studies in 1984, demonstrating increased circulating levels of embryonic ρ-globin in chickens 
treated with both butyrate and 5-azacytidine317. A study in 1995 showed that administration 
of arginine butyrate 6 days a week for an average of 10 weeks in humans, resulted in increased 
γ-mRNA and foetal haemoglobin (HbF) containing reticulocytes, but there was no significant 
haematological response in either sickle cell disease (HbSS) or severe β-thalassemia318. 
In vitro culture of definitive erythroid burst forming units (BFU-E) reveals that application of 
any SCFAs of carbon chain length 3 through 9 induces a response, but most significantly those 
of a carbon chain length 5 or less as measured by γ-globin positive erythroblasts and γ-
mRNA319. The application of acetate, a product of butyrate catabolism, induces a dose 
response increase of γ-globin expression in murine adult, umbilical cord blood and HbSS 
cells320. Culture of K562 cells has reveals that 3-5 carbon SCFAs specifically enhance activity of 




the γ-globin promoter region321 with a less response noted for phenylacetate application and 
that both isobutyrate and 6-carbon caproate require higher doses to induce a notable effect.  
Dose escalation studies in baboons reveal that minimal toxicity resulted from doses of butyric 
acid up to 4g/kg/day, with EPO having an additive effect. This dosing regimen results in a mean 
HbF increase of 1.9% to 5.3% and the number of reticulocytes containing HbF, increasing from 
1% to 21.6% in non-anaemic animals322. The structurally related compound and histone 
deacetylase inhibitor, valproic acid (used for the treatment of epilepsy), causes increased HbF 
with a mean HbF of 10.4% across 36 epileptic patients at doses of 10-46mg/kg/day, in 
comparison to a mean of 3.3% in normal subjects323. Its application has been reported as 
increasing the efficacy of in vitro HSC culture324.  
1.3.6.1 Short Chain Fatty Acids and Foetal Haemoglobin  
The switch from foetal to adult haemoglobin generally occurs in utero between 28 and 34 
weeks. In  hyperinsulinaemia and high serum butyrate conditions a  delay in this switch has 
been observed in 9 out of 10 infants born to diabetic mothers325.  Follow-up reports show a 
similar butyrate-induced switch delay in a foetal lamb model326 and increased expression of 
HbF genes in HbSS and thalassemia patient derived erythroblasts culture treated with sodium 
butyrate327.  
1.3.6.2 Synergistic Compounds  
5-azacytidine  induces changes in the differentiation state of cultured ESCs, inhibition of 
methylation of newly synthesised DNA328 and promotes de-methylation of modified DNA 
histone tails. Methylation (and acetylation) of DNA histone tails modifies their interaction with 
other proteins, thus de-methylation may have the capacity to reverse the silencing of 
embryonic genes in adult cells. Other studies demonstrate 5-azacytidine application as a 
prerequisite in a butyrate-induced increased transcriptional activity of the embryonic ρ-globin 
in adult erythroid cells329 and as an enhancing factor in response to α-amino-N-butyric acid (α-
ABA) in normal and anaemic primates in vivo as well as in vitro erythroid progenitor cultures330. 
EPO plays an important role in delaying erythroid apoptosis induced by α-globin precipitation 
331, 332, prolonging survival and inducing proliferation. These studies underscore the benefit of 
combined therapy to achieving optimal outcomes for blood disorder patients.  In 2005, a 
clinical trial333 demonstrated increased HbF following concurrent butyrate and  EPO 




administration, particularly in β+-thalassemia  patients with both low endogenous EPO levels 
(<145mU/mL) and low HbF levels (<30%). 
1.3.6.3 Short Chain Fatty Acid Derivatives 
Butyrate, possesses the capacity for bulk histone H4 acetylation and induction of growth 
suppressing p21 expression313 which is not observed in the application of SCFA derivatives315. 
SCFA derivatives increase overall erythrocyte count and haematocrit as well as F-
reticulocytes/γ-globin mRNA in anaemic baboons and transgenic mice containing the human 
β-globin gene locus312. SCFA derivatives are clinically favourable as they lack the growth 
inhibitory effects of SCFA compounds315 whilst exhibiting higher oral bioavailability and 
resistance to metabolism334. 
The carbon-based small compounds, phenylakyl acids, phenyoxyacetic acid and phenylacids, 
induced similar effects on HbF expression at lower concentrations334 that are resistant to 
oxidative metabolism whilst not replicating SCFA-induced G1 cell cycle arrest310, 335-339 and 
hindering proliferation through disruption of cellular metabolic transport pumps340, 341.  
Dover et al.342, 343, in two clinical reports, show HbF induction in children treated with sodium-
4-phenylbutyrate for urea-cycle disorders and in sickle cell patients. The use of sodium-4-
phenylbutyrate, however, is limited by its myelotoxicity and rapid metabolism meaning that a 
continuous infusion or oral protocol requiring 30-40 tablets daily is required342, 343. 
Phenylacetate and 4-phenylbutyrate are shown to increase HbF in K562 cells344, normal, 
thalassemia, and HbSS erythroid precursors. It is suggested that greater efficacy could be 
achieved by the substitution of the phenyl ring with chlorine to increase the lipophilicity of the 
drug338.  
1.3.6.4 Mechanisms of Action of Short Chain Fatty Acids 
Studies aimed at revealing the molecular mechanisms of SCFA have produced varied results. 
In the culture of IL-3 dependent 32D cell line, Boosalis et al.315 demonstrate the effectiveness 
of SCFA derivatives in inducing γ-globin expression with prolonged STAT5 phosphorylation and 
consequent expression of growth promoting c-myc and c-myb genes. These compounds, along 
with butyrate, are said to stimulate the EPO signalling pathway down-stream of EPOR and JAK-
2315.  




Dempsey et al.345 also report increased εγ-CACCC promoter region activity in SCFA-treated 
murine erythroleukaemia (MEL) cells. In contrast to the work of Boosalis et al.315 this study 
demonstrates that increased promoter activity is independent of STAT5 signalling. The authors 
suggest that SCFA may instead mediate γ-globin inducing effects through modification of adult 
erythroid transcription factors, including EKLF, SP1, and SP3, with the former two appearing to 
undergo acetylation following treatment with SCFA. In a similar study, Bhatia et al.346 report 
that the ρ-globin and γ-globin inducing effects of SCFA are enhanced in the presence of EPO 
and insulin. This SCFA+ EPO/insulin treatment regime resulted in modulation of histone 
acetylation but no differential activation of STAT5 signalling or the previously indicated 
mediators p42/44 and p38. A further report confirms that despite p38 inhibitor disruption of 
cellular pathways essential to induction of HbF, with the activation of p38 not being the 
mediator of SCFA effects347.  
1.3.6.5 JAK-STAT and SCFA in Infantile Haemangioma 
The biology of IH has been elucidated in greater detail recently with many innate modulators. 
The rapid growth and gradual involution of IH have been attributed to the crucial role for the 
RAS. The JAK-STAT pathway that has been implicated in both aberrant tumour proliferation 
and haematopoietic activity (particularly in primitive haematopoiesis), is yet to be reported in 
IH. SCFA have been studied for almost four decades for inducing differentiation of 
erythropoietic cells. Whilst the mechanism of action remains unclear, it has been suggested 
that such differentiation may be induced via the JAK-STAT signalling pathway315.  
Previous investigation as to the activity of the JAK-STAT pathway within IH has demonstrated 
the localisation of total STAT3 protein to endothelium of activity proliferating IH265, 348, an 
increase in phosphorylation and nuclear translocation of each of the STATs 1, 3 and 5 in IHMSC 
with application of IFN-α2b265 and the unique effect of VEGF in increasing phosphorylation and 
nuclear translocation of STAT1 in IHMSC265. Vishvanath265 proposed a model of IH 
development, in which increased VEGFR-2, STAT-3 and pSTAT3 are associated with IH 
proliferation whilst increased STAT-1 signalling is alternately observed as the lesion involutes 
and consequently apoptosis. Further investigation of the involvement of the JAK-STAT 
signalling pathway in IH aims to further elucidate the biology of this enigmatic condition. 
Further investigation into the innate function of haemangioblasts and HE will contribute to a 
greater understanding and efficiency of ex vivo haematopoiesis. The successful in vitro 




differentiation of IHEDCs down various lineages suggest that IH culture may prove a valuable 
source of pluripotent stem cells. The use of IH as a human model for erythropoiesis enables 
the in vitro differentiation inducing effect of SCFA to be studied in a haemangioblast model and 
comparison to be drawn between IHEDCs and haematopoietic precursors from other 
haematopoietic models and developmental stages. 
  




1.4 Aims  
This present study aimed to investigate the haematopoietic differentiation potential of IHEDCs 
in vitro. SCFAs, the 4-carbon butyrate and the 3-carbon propionate, will be administered to 
IHEDCs in culture and their effects on proliferation, differentiation and JAK-STAT pathway 
activity will be investigated. This study will also investigate the expression of the three STAT 
proteins, STAT1, STAT3 and STAT5, and their activated forms in all phases of IH development.  
1.5 Hypotheses 
With the previous demonstration of both primitive erythropoiesis arising from IH in vitro, and 
identification of an active HE within IH, it is hypothesised that IHEDCs can be successfully 
differentiated to form erythrocytes, likely both in the presence and absence of additional 
cytokines. It is hypothesised that the application of SCFAs will hasten this differentiation 
process.  
Expression of pSTAT1 is expected only in minimal quantities. Myeloid cells have previously 
been identified within IH and thus the secretion of IFNs which signal up-stream of STAT1 and 
promote its activation, is possible. Previous investigation of the expression of STAT1265 in IH 
allows the hypothesis that expression of activated STAT1 is likely to increase as the lesion 
involutes.  
Previous reports of STAT3 have highlighted its activity as an oncogene in malignant tumours. 
Based on such observations, it is expected that pSTAT3 will be expressed in the proliferating 
phase of IH, corresponding to its rapid growth. The identification of pSTAT3 in stem cells and 
previously localisation of IHMSCs to the perivascular layer of IH prompts the hypothesis that 
pSTAT3 will be expressed in the perivascular region. However, based on previous expression 
of STAT3 within IH as localised to the capillary endothelium of the proliferating phase265, 348 of 
IH it is most likely that pSTAT3 will be revealed in the greatest quantity in the endothelial nuclei 
in IH. pSTAT3 expression is expected to decrease as IH involutes.  
It is hypothesised that IH tissue predominantly expresses the activated form of STAT5 as its 
expression relates to down-stream signalling of the EPOR, which has already been 
demonstrated to be expressed present on the endothelium of IH. pSTAT5 expression is 
expected to be highest in the proliferative phase of IH as this has been previously identified to 
have an active HE. 




2 Chapter 2 Materials and Methods 
2.1 Materials 
2.1.1 Tissues 
This study was approved by the Central Regional Health and Disability Ethics Committee. Tissue 
samples used were obtained from the Gillies McIndoe Research Institute (GMRI) Tissue Bank. 
Such tissues were obtained with consent from patients undergoing surgical resection of IH 
lesions.  
Formalin-fixed and paraffin-embedded IH tissues were used for IHC staining. Snap-frozen IH 
tissue samples stored at -80°C were used for 1DE-WB and NanoString analysis. Fresh IH tissue 
from one patient was used for explant culture. This was transferred to the laboratory in 
disinfectant media following surgical removal and promptly established in explant culture. The 
demographic details of patients whose IH tissues were used for this study, is outlined in Table2 
.1.  
Table 2.1. Demographic Details of Patients Whose IH Tissues Were Used for This Study 
SampleTypes      Investigations Age  Mean Age Median Age Gender 
Proliferating (n=8)   IHC 3 -16 months 8 months 8 months 2M, 6F 
Involuting (n=2)   IHC 3 -5 years 4 years 4 years 2F 
Involuted (n=8)   IHC 4 -59 years 15.5 years 11.5 years 1M, 7F 
Proliferating (n=3)   WB 5 - 7 months 6 months 6 months 3F 
Involuting (n=3)   WB 16 months  
-3 years 
22 months 16 months 1M, 2F 
Involuted (n=3)   WB 5 - 7 years 5.6 years 5 years 1M, 2F 
(Proliferating (n=1)   TC  8 months   F 
WB, Western Blot; IHC, immunohistochemical staining; TC, tissue culture 
 





The source, species, optimal dilutions and control tissues of the primary and secondary antibodies used in immunofluorescent (IF) and 4', 6-diamidino-
2-phenylindole (DAB) immunohistochemical (IHC) staining, immunocytochemical (ICC) staining and 1 dimensional electrophoresis-Western Blotting 
(1DE-WB) in this study and listed in Table 2.2. 
Table 2.2 Primary and Secondary Antibodies; Species, Sources, Concentrations and Control Tissues 




Control  Sources 
Abcam Goat α-Mouse (cat# ab6788) Goat IgG 1:1000 1:1000 1:400  Cambridge, MA, 
USA 
Abcam Goat α-Rabbit (cat# ab97196) Goat IgG pAb 1:200 1:200 1:400  Cambridge, MA, 
USA 
Abcam α-glycophorin A+B  
(cat# ab15009) 
Mouse IgG mAb 1:2000 1:2000 - Tonsil Cambridge, MA, 
USA 
Abcam α-SMA (cat# ab15734) Rabbit IgG pAb 1:200 1:200 -  Cambridge, MA, 
USA 
Ambion® by Life Technologies α-β-Actin  
(cat# AM4302) 
Mouse IgG mAb 1:200 1:200 1:400  Carlsbad, CA, USA 
Cell Signalling Technology® α-pSTAT1  
(cat #9167S) 
Rabbit IgG mAb 1:400 1:800 1:1000 Tonsil Danvers, MA, USA 
Cell Signalling Technology® α-pSTAT3  
(cat #9145) 
Rabbit IgG mAb 1:100 1:400 1:2000 Tonsil Danvers, MA, USA 
Cell Signalling Technology® α-pSTAT5  
(cat# 9314) 
Rabbit IgG mAb 1:200 1:400 1:1000 Tonsil Danvers, MA, USA 




Cell Signalling Technology® α-Total 
STAT5 (cat# 9363) 
Rabbit IgG pAb - - 1:1000  Danvers, MA, USA 
Leica α-CD34 (cat# PA0212) Mouse IgG mAb RTU RTU - Placenta Nussloch, Germany 
Merck Millipore α-Total STAT3  
(cat# 06596) 
Rabbit IgG pAb 1:100 1:100 1:500  Billerica, MA, USA 
Novus Biologicals  α-Total STAT1  
(cat# NBP1-48013) 
Mouse IgG mAb 1:100 1:50 1:2000  Littleton, CO, USA 




2.1.3 Autostainer Kits 
Autostainer Kits used in IHC as conducted on a Leica ASP200S Autostainer are listed below 
(Table 2.3).  









Product  Source Location  
Leica Bond Epitope Retrieval Solution 1 (cat # AR9961) Nussloch, Germany 
Leica Bond Epitope Retrieval Solution 2 (cat# AR9640) Nussloch, Germany 
Leica Bond Polymer Refine Detection Ki (cat# DS9800)t Nussloch, Germany 
Leica Bond Polymer Refine Red Detection Kit (cat# DS9390) Nussloch, Germany 




2.1.4 Western Blotting Solutions 
BioRad and iBind systems were used in combination for 1DE-WB in this study. Consumables 
used in this technique and listed in Table 2.4.  
Table 2.4 Consumables used for 1DE-Western Blotting 
2.1.5 RNA Extraction Kits  
RNA for Nanostring gene analysis was extracted using the kits listed in Table 2.5.  
Table 2.5 RNA Extraction Kits  
Product  Source Location  
Qiagen RNase-Free DNase Set (cat# 79254) Venlo, Netherlands 
Product  Source Location  
BioRad 2 x Laemmli Sample Buffer (cat# 161-0737) Hercules, CA, USA 
BioRad Mini PROTEAN® TGX™ Precast Gel (cat# 456-1083) Hercules, CA, USA 
BioRad 10x Tris/Gylcine/SDS Buffer (cat# 161-0732) Hercules, CA, USA 
BioRad Clarity™ Western ECL Substrate Solution (cat# 170-5060) Hercules, CA, USA 
BioRad Mini PROTEAN® Tetra Cell (cat# 165-8004) Hercules, CA, USA 
BioRad Precision Plus Protein Dual Colour Standard (cat# 161-0374) Hercules, CA, USA 
BioRad Trans-Blot® Turbo™ Mini PVDF Transfer Pack (cat# 170-4156) Hercules, CA, USA 
BioRad Trans-Blot® Turbo™ Transfer System (cat# 170-4155) Hercules, CA, USA 
BioRad β-mercaptoethanol (cat# 161-0710) Hercules, CA, USA 
GE Healthcare IPG Buffer pH 3-10 (cat# 17600087) Piscataway, NJ, USA 
Life Technologies iBind™ Cards (cat# SLF1010) Carlsbad, CA, USA 
Life Technologies iBind™ Fluorescent Detection Solution Kit  
(cat# SLF1019) 
Carlsbad, CA, USA 
Life Technologies iBind™ Solution Kit (cat# SLF1020) Carlsbad, CA, USA 
Life Technologies™ Molecular Probes® Qubit® Protein Assay Kit  
(cat# Q33211) 
Carlsbad, CA, USA 
Sigma-Aldrich RIPA Buffer (cat# R0278) St Louis, MO, USA 
Thermo Scientific Halt™ Protease and Phosphotase Inhibitor  
(cat# 1861281) 
Waltham, MA, USA 




Qiagen RNeasy Mini Kit (cat# 74106) Venlo, Netherlands 
 
2.1.6 Chemicals, Reagents and Stains 
Chemicals, Reagents and Stains used in this study are listed in Table 2.6.  
Table 2.6 Chemicals, Reagents and Stains  
Product  Source Location  
Corning Discovery Labware dispase (cat# 354235) Tewksbury, MA, USA 
Corning® Matrigel® Matrix (cat# 354234) Tewksbury, MA, USA 
Emsure potassium chloride (cat# 7447-40-7) Darmstadt, Germany 
Emsure sodium chloride (cat# 7647-14-5) Darmstadt, Germany 
Gibco® by Life Technologies foetal bovine serum (cat# 10091-148) Carlsbad, CA, USA 
Gibco® by Life Technologies gentamicin/amphotericin solution  
(cat# R-015-10) 
Carlsbad, CA, USA 
Gibco® by Life Technologies Penstrep (cat# 15140122) Carlsbad, CA, USA 
Gibco® by Life Technologies 10x phosphate buffered saline pH7.2  
(cat# 70013-032) 
Carlsbad, CA, USA 
Gibco® by Life Technologies RPMI medium 1640 (+ L-Glutamine) Carlsbad, CA, USA 
Life Technologies Prolong® Gold Antifade with DAPI Carlsbad, CA, USA 
Merck kGaG acetone (cat# UN1090) Darmstadt, Germany 
Merck kGaG butyric acid (cat# UN2820) Darmstadt, Germany 
Merck kGaG propionic acid (cat# UN3463) Darmstadt, Germany 
Molecular Probes by Life Technologies 0.4%trypan blue stain  
(cat# T10282)  
Carlsbad, CA, USA 




Sigma Life Science DMSO (cat# D8418-50ml) St Louis, MO, USA 
Sigma-Aldrich bovine serum albumin (cat# 9048-46-8) St Louis, MO, USA 
Sigma-Aldrich MCDB 131 (cat# M8537) St Louis, MO, USA 
Sigma-Aldrich sodium  bicarbonate (cat# S5761-500G) St Louis, MO, USA 
Sigma-Aldrich sodium borohydride (cat# 16940-66-2) St Louis, MO, USA 
Sigma-Aldrich sodium citrate (cat# 6132-04-3) St Louis, MO, USA 
Sigma-Aldrich Tris hydrochloride (cat# 3098T-B7) St Louis, MO, USA 
Sigma-Aldrich Tween 20™ (cat# P1379-1L) St Louis, MO, USA 
Thermo Scientific Richard-Allan Scientific™ eosin (cat# 7111) Kalamazoo, MI, USA 
Thermo Scientific Richard-Allan Scientific™ haematoxylin  
(cat# 7211) 
Kalamazoo, MI, USA 
TMK Packers Ltd ethanol (cat# 1170-SDA3A) Auckland, NZ 
TMK Packers Ltd xylene (cat# 1307-X) Auckland, NZ 
 
  




2.1.7 Plastic- and Glass-ware 
The plastic- and glass-ware used in this study and their sources are listed in Table 2.7. 
Table 2.7 Plastic- and Glass-ware  
Product  Source Location  
Corning® Centristar 15mL centrifuge tubes (cat# 430791) Corning, NY, USA 
Eppendorf™ DNase and RNase free 1000μL pipette tips  
(cat# 022491253) 
Waltham, MA, USA 
Eppendorf™ DNase and RNase free 10μL pipette tips  
(cat# 022491202) 
Waltham, MA, USA 
Eppendorf™ DNase and RNase free 200μL pipette tips  
(cat# 022491296) 
Waltham, MA, USA 
Eppendorf™ DNase and RNase free 20μL pipette tips  
(cat# 022491270) 
Waltham, MA, USA 
Ibidi 8-well culture u-slide (cat# 80826) Martinsried, Germany 
Invitrogen Countess™ cell counter chamber slides (cat# C10228) Carlsbad, CA, USA 
Jet BioFil sterilised syringe driven 0.22μm filters (cat# FPE-204-030) Guangzhou, China 
Jet BioFil® tissue culture treated 12-well plate (cat# TCP00192) Guangzhou, China 
Jet BioFil® tissue culture treated 24-well plate (cat# TCP010024) Guangzhou, China 
LabCon 50mL centrifuge tubes (cat# 3186-345-008) Petaluma, CA, USA 
Leica Bond Plus microscope slides (cat# 00270) Nussloch, Germany 
Leica Surgipath™ pre-cleaned coverslips (cat# 958877) Nussloch, Germany 
Thermo-Scientific Cytospin™ shandon single cytofunnel  
(cat# 5991040) 
Waltham, MA, USA 
Thermo-Scientific Cytospin™ slides (cat# 5991056) Waltham, MA, USA 




Thomas Scientific glass tissue grinder (cat# 3431D70)  Swedesboro, NJ, U.S.A 
VWR microcentrifuge tubes (cat# 89000-028) Radnor, PA, USA 
VWR Next Generation 1000μL pipette tips (cat# 613-0738) Radnor, PA, USA 
VWR Next Generation 200μL pipette tips (cat# 613-0732) Radnor, PA, USA 
 
  




2.1.8 Laboratory Equipment 
Laboratory equipment used in this study is listed in Table 2.8. 
Table 2.8 Laboratory Equipment and Their Sources 
Product  Source Location  
BioRad ChemDoc™ XRS  Imaging System (cat# 170-8265) Hercules, CA, USA 
Ika® Vortex Genius 3 Selangor, Malaysia  
Invitrogen Countess™ Automated Cell Counter  Carlsbad, CA, USA 
Lab Companion BW-20B Waterbath (cat# REVQ-20WB) Seoul, Korea 
Leica ASP200S Autostainer Nussloch, Germany 
Leica DFC290 HD Camera Nussloch, Germany 
Leica DMIL LED Microscope  Nussloch, Germany 
Leica RM 2235 Microtome Nussloch, Germany  
Life Technologies iBind™ Western Device (cat# SLF1000) Carlsbad, CA, USA 
Olympus BX53 Bright Field Microscope  Tokyo, Japan 
Olympus FV1200 Confocal Microscope  Tokyo, Japan 
Olympus SC100 10.6 Megapixel Colour Camera Tokyo, Japan 
Systec DX-45 Autoclave Wettenberg, Germany 
Thermo-Scientific Cytospin™ 4 Cytocentrifuge Waltham, MA, USA 
Thermo-Scientific FORMA Stericult CO2 Incubator Waltham, MA, USA 
Thermo-Scientific HeraEUS Fresco 17 Centrifuge Waltham, MA, USA 
Thermo-Scientific HeraEUS Megafuge 16 Centrifuge Waltham, MA, USA  




Thermo-Scientific HeraEUS Pico 17 Centrifuge Waltham, MA, USA 
Thermo-Scientific NanoDrop 2000 Spectrometer  Waltham, MA, USA 
 
  





2.2.1 Infantile Haemangioma Tissues and Explant Culture 
Fresh IH tissue was cleansed of debris using phosphate buffered saline (PBS) and transported 
in MCDB 131 media (Sigma-Aldrich) containing 1.18g/L sodium bicarbonate (Sigma-Aldrich), 
10% Penstrep (Gibco by Life Technologies), and 25μg/mL Gentamicin/Amphotericin solution 
(Gibco by Life Technologies). All culture work was conducted under sterile conditions in a 
laminar flow cabinet (Thermo Scientific). 
2.2.1.1 Infantile Haemangioma Explant Culture  
Fresh IH tissue was sectioned at room temperature into 1mm3 pieces and cultured according 
to protocol described by Tan et al23.  75μL of Matrigel (Corning, Tewksbury), thawed overnight 
at 4°C, was alliquoted into alternate wells of a 24-well culture plate and incubated at 37°C for 
15 mins to allow matrix solidification before embedding of IH tissue.  A single 1mm3 explant 
piece was laid on solidified matrix for 20 mins prior to the application of a further 75μL of 
Matrigel (Corning) on top of the explant. 250μL of appropriate media was dispensed per well 
and changed every 3-4 days. Culture plates were incubated at 37°C, 80% relative humidity (RH) 
and 3% CO2 in a FORMA Stericult CO2 Incubator (Thermo Scientific). Following 15 - 60 days in 
culture, IHEDCs were harvested for the functional erythropoiesis experiments.  
2.2.1.2 Dispase Protocol 
Dispase (Corning Discovery Labware), a protease that can gently release cells from the matrix 
and also those adherent to the culture plastic, was used to harvest them for evaluation or  
passaging and expansion. Liquid media was removed and 150μL of Dispase was added to each 
well and incubated for 7 mins at 37°C. Dispase (Corning Discovery Labware) activity was 
quenched by dilution with the addition of 1mL of appropriate media to each well. Well contents 
were collected in 15ml centrifuge tubes (Corning Centristar) after washing, with an additional 
1ml of media and centrifuged at 800xg for 5 mins. Supernatants were discarded and the cell 
pellets were re-suspended in 0.5ml of appropriate media.  
2.2.1.3 Tissue Culture Media 
Media used in this study included both RPMI media (Gibco by Life Technologies) and MCDB 
131 media (Sigma-Aldrich). RPMI media (Gibco by Life Technologies) was obtained from the 
manufacturer in liquid form and stored at 4°C prior to use. 11.6g of MCDB 131 media (Sigma-




Aldrich) was reconstituted with dH2O to a final volume of 1L with the addition of 1.18g/L 
sodium bicarbonate (Sigma-Aldrich). 2% Penstrep (Gibco by Life Technologies) was added to 
both media prior to sterile filtration using a 0.22μM filter (Jet BioFil).  
2.2.2 IHEDC Cultures  
IHEDCs harvested from tissue culture were cultured in a range of concentrations of the short 
chain fatty acids, butyric acid (Merck kGaG, Darmstadt, Germany) and propionic acid (Merck 
kGaG). IHEDCs were harvested from IH explant culture as required using the Dispase protocol 
described in Section 2.1.3. The cell suspension was quantified using a Countess Cell Counter 
(Invitrogen) and alliquoted at a volume equivalent to 50,000 live cells onto 150μL of solidified 
Matrigel (Corning) in alternate chambers of a 24-chamber culture plates. After 24 hrs (to allow 
cell seeding) cytokine containing media was applied. For each experiment, a negative control 
consisted a culture in media without addition of cytokines and a positive control consisted a 
media containing DMSO (Sigma Life Science) at 0.05M316. For SCFA containing media, 
appropriate concentrations of butyric acid or propionic acid were achieved by dilution. Media 
was sterile-filtered and prepared at twice the experimental concentration to ensure that at the 
time of the media change, the removal and the replacement of half of the volume of the 
existing media would achieve the desired cytokine concentration. All cultures were incubated 
in a SteriCult Incubator (Thermo Scientific) at 37°C, 80% RH and 5% CO2. At the conclusion of 
each experiment/time point of interest the contents of each culture well were harvested using 
a Dispase protocol and the total number of viable cells calculated using the Countess Cell 
Counter. Remaining cell suspensions were retained for further evaluation (ICC or 1DE-WB) or 
disposed of appropriately.  
2.2.2.1 Preliminary Cultures 
Preliminary cultures were used to optimise culture conditions. Media used included RPMI 
media (Gibco by Life Technologies), 1mM FeSO4 in RPMI media (Gibco by Life Technologies) 
and MCDB131 media (Sigma-Aldrich) with a range of concentrations (0.05mM - 2mM) of either 
butyric acid (Merck kGaG) or propionic acid (Merck kGaG). Cells were harvested using the 
Dispase protocol desdcribed in Section 2.2.1.2 and quantified at 24, 48, 72 and 96 hrs after the 
first addition of cytokine-containing media. Media was changed every 24 hrs as described 
above.  




2.2.2.2 IHEDCs Cultures with Administration of SCFAs 
The optimised cultures followed the above protocol using MCDB 131 media (Sigma-Aldrich) 
and a concentration of 1mM for either butyric acid (Merck kGaG) or propionic acid (Merck 
kGaG) and cells were harvested and quantified at 24 and 72 hrs.  
2.2.2.3 Preparation of Cytokine Containing Media  
2.2.2.3.1 DMSO  
DMSO (Sigma Life Science) (78.13g/M) was used as a positive control in cell culture at a 
concentration of 0.05M. Media was made up at twice this concentration, allowing only half the 
volume of the existing media in the experimental well to be removed at each media change. 
This was achieved by the addition of 8.24mL of DMSO (Sigma Life Science) (1.10g/ml) per litre 
of appropriate media (MCDB131 media (Sigma-Aldrich) or RPMI media (Gibco by Life 
Technologies) +/- iron) with 2% Penstrep2% (Gibco by Life Technologies).   
2.2.2.3.2 Butyric Acid and Propionic Acid 
A 109mM stock solution of butyric acid (Merck kGaG) (88.1g/M) was prepared by a 1 in 100 
dilution of butyric acid (Merck kGaG) (0.96g/ml).  Butyric acid (Merck kGaG) concentrations of 
0.2mM, 1mM and 2mM were achieved by addition of 1.85ml, 9.25ml or 18.5ml of stock 
solution per litre of culture media, respectively. 
A 134mM stock solution of propionic acid (Merck kGaG) (74.08g/M) was prepared by a 1 in 
100 dilution of propionic acid (Merck kGaG) (0.99g/ml). Propionic acid (Merck kGaG) 
concentrations of 0.2mM, 1mM and 2mM were achieved by 1.49ml, 7.46ml and 14.9ml of 
stock solution per litre of culture media, respectively.  
2.2.2.3.3 Iron-Enriched RPMI Media 
Sterile RPMI media (Gibco by Life Technologies) was enriched with iron to achieve a final 
concentration of 1μM Fe2+ in culture media achieved serial dilution. A 1mM stock solution of 
FeSO4 (278g/mol) was established by dissolving 0.28g of FeSO4 per ml of sterile RPMI (Gibco 
by Life Technologies). 1ml of the 1mM FeSO4 in RPMI stock solution was added per ml of RPMI 
media prior to the addition of cytokines, resulting in a final concentration of 1μM Fe2.    




2.2.3 Western Blotting 
2.2.3.1 Protein Extraction  
Protein was extracted by homogenisation of 10mg of snap-frozen IH tissues in 250μL of 
extraction buffer consisting of RIPA buffer (Sigma-Alrich) with 1% HALT™ Protease and 
Phosphatase inhibitor cocktail (Thermo Scientific) on ice. Contents was then centrifuged at 
17,000xg at 4°C for 20 mins. The protein containing supernatant (lysate) was then aliquoted 
for 1DE-WB analysis or stored at -80°C until required and the pellet was discarded. Protein 
concentration was calculated using a Qubit™ fluorometer (Life Technologies Molecular Probes) 
calibrated to a standard curve using standard protein samples in a Qubit Protein Assay Kit (Life 
Technologies Molecular Probes, Carlsbad, CA, USA). Protein samples for analysis were 
prepared by the addition of 10μL of protein lysate to 190μL Qubit working solution (Life 
Technologies Molecular Probes). To ensure equal total protein in each well, the volume of each 
sample lysate equivalent to required protein is made up to 10μL with extraction buffer.  
2.2.3.2 Gel Electrophoresis 
To each 10μL lysate sample, 9.5μL of Laemmli buffer (BioRad, Hercules, CA, USA) and 0.5μL of 
β-mercaptoethanol (BioRad) was added, prior to heating at 95°C for 5 mins. For gel 
electrophoresis equal volumes of the samples were added to individual lanes of a Protean TGX 
Mini Gel (Biorad) with lane 1 receiving 5μL of Protein Standard (BioRad). The gel was 
electrophoresised first at 110V for 5 mins, then at 150V until the samples have moved through 
the entire gel (approx. 30 mins) in a Mini PROTEAN® Tetra Cell (Biorad). 
2.2.3.3 Semi Dry Transfer 
Proteins were then transferred from the gel to a PVDF membrane (Biorad), using a TransBlot 
Turbo Transfer System (Biorad) at 1.3A, 25V for 7 mins (15 mins when investigating large 
molecular weight proteins >70kDa).  
2.2.3.4 Antibody Incubation 
PVDF membranes (BioRad) were incubated with primary and secondary antibodies 
concurrently using an iBind system (Life Technologies iBind). iBind solution was prepared by 
the addition of 300μL of iBind additive(Life Technologies iBind) and 6mL of iBind buffer (Life 
Technologies iBind) to 23.7mL distilled water. Blotted membrane was immersed in iBind 
solution for 10 mins. The iBind card (Life Technologies iBind) was then placed on the stage and 




dampened with 6mL of iBind solution prior to mounting of the blotted membrane protein side 
down. Primary and secondary antibodies were prepared at appropriate concentrations in 
separate 2mL iBind solution preparations and loaded in lanes 1 and 3 respectively. Lane 2 and 
4 each received 2mL and 6mL of iBind solution respectively. The iBind system (Life 
Technologies iBind) was incubated overnight at room temperature. The iBind system (Life 
Technologies iBind) relies on osmosis to draw these liquids successively through the 
membrane, equivalent to application of primary and secondary antibody with washing after 
each application to remove unbound antibody.  
2.2.3.5 Imaging and Data Analysis 
The incubated membrane was then rinsed in tap water for 5 mins prior to application of Clarity 
Substrate Kit (BioRad) for 15 mins and capture of chemiluminescent signals using a ChemiDoc™ 
MP Imaging System (BioRad) and ImageLab™ software (BioRad).  
2.2.4 Immunohistochemical and Immunocytochemical Staining 
2.2.4.1 Slide Preparation 
4μm-thick FFPE IH tissues sections were cut using a Leica RM 2235 Microtome (Leica), floated 
in a water bath and transferred onto Bond Plus (Leica) slides prior to overnight drying at room 
temperature.  
For ICC staining, cells were spun onto pre-coated Cytospin slides (Thermo Scientific) using a 
Cytospin Centrifuge (Thermo Scientific) at suspension volume equivalent to 50,000 live cells. 
Cells were fixed with acetone (Merck kGaG) prior to antigen blocking and incubation with 
primary and secondary antibodies as per IHC staining protocol.  
2.2.4.2 Autostainer Immunohistochemical Staining 
A Leica ASP200S Autostainer (Leica) was used alongside manual staining techniques to allow 
efficient staining of slides. DAB IHC staining in this study was performed exclusively using Leica 
Autostainer (Leica) techniques as specified by the manufacturer. Slides were prepared for 
autostaining by dewaxing and heat induced epitope retrieval using Bond Epitope retrievals 
(Leica).  
All protocols including IF IHC staining used Bond Polymer Refine Ready-to-use Detection Kit 
(Leica) which contained all components. For double staining Bond Polymer Refine Red Ready-
to-Use Detection Kit (Leica) was used additionally. Generally, antibodies with secondary 




fluorophores for IF IHC staining were applied at appropriate dilutions in Bond Primary Antibody 
Dilutent (Leica). Slides were peroxide blocked and incubated with primary antibody followed 
by incubation with post primary AP to enable signal amplification. After Bond Wash, 
amplification polymer was applied and subsequent to further washing Mixed DAB refine was 
applied (or secondary flurophores in the case of IF IHC staining). Slides were counter-stained 
with haematoxylin prior to cover slipping.  
A total of four protocols were employed for different IHC staining methods and these are 
outlined below: Leica Autostainer F Protocol (Table 2.9), Leica Autostainer TF Protocol (Table 
2.10), Leica Autostainer J Protocol (Table 2.11) and Leica Autostainer IF Protocol (Table 2.12).    




Table 2.9 Leica Autostainer F Protocol - Routine IHC Staining  
Solution Applied Incubation Period 
Peroxide Block 5 mins 
Primary Antibody  15 mins 
Post Primary AP 8 mins 
Bond Wash 3x2 mins 
Amplification Polymer  8 mins 
Bond Wash 2x2 mins 
Mixed DAB refine Chromogen Substrate (Red) 10 mins  
Haematoxylin Counter Stain  5 mins  
 
Table 2.10 Leica Autostainer TF Protocol – Long Antibody Incubation 
Solution Applied Incubation Period 
Peroxide Block 5 mins 
Primary Antibody  45 mins 
Post Primary AP 8 mins 
Bond Wash 3x2 mins 
Amplification Polymer  8 mins 
Bond Wash 2x2 mins 
Mix DAB refine Chromogen Substrate (Brown) 10 mins  
Haematoxylin Counter Stain  5 mins  
  




Table 2.11 Leica Autostainer J Protocol – DAB IHC Staining for Using Two Primary Antibodies  
Solution Applied Incubation Period 
Peroxide Block 5 mins 
1 of 2 Primary Antibody  15 mins 
Post Primary AP 8 mins 
Bond Wash 3x2 mins 
Amplification Polymer  8 mins 
Bond Wash 2x2 mins 
Mixed DAB refine Chromogen Substrate (Brown) 10 mins  
2 of 2 Primary Antibody 15 mins 
Post Primary AP 20 mins 
Bond Wash 3x2 mins 
Amplification Polymer  30 mins 
Bond Wash 1x5 minutes, 1x2 mins 
Mixed Red refine Chromogen Substrate (Red) 10 mins  
Mixed Red refine Chromogen Substrate (Red) 5 mins  










Table 2.12 Leica Autostainer IF Protocol – IF IHC Staining Using Two Antibodies   
Solution Applied Incubation Period 
Bond Wash 2x5 mins 
Peroxide Block 5 mins 
Bond Wash 5 mins 
Peroxide Block 5 mins 
Bond Wash 5 mins 
1 of 2 Primary Antibody  60 mins 
1 of 2 Primary Antibody  60 mins 
2 of 2 Primary Antibody  60 mins 
2 of 2 Primary Antibody  60 mins  
Bond Wash 5 mins 
1 of 2 Secondary Flurophore  60 mins 
2 of 2 Secondary Flurophore  60 mins 
Bond Wash 5 mins 
  




2.2.4.3 Manual Immunofluorescent Immunohistochemical Staining 
For manual IHC staining slides underwent routine de-parrifinisation and re-hydration as 
outlined in Table 2.13 prior to antigen retrieval and application of antibodies.  
Table 2.13 De-parrifinisation and Re-hydration for Manual IF IHC  
Solution Applied Incubation Period 
Xylene 2 mins 
Xylene 2 mins 
100% ethanol 2 mins 
90% ethanol 2 mins 
80% ethanol 2 mins 
70% ethanol 2 mins 
Distilled water 2 mins 
Distilled water  2 mins 
 
Following de-paraffinisation and rehydration slides were rinsed in 1 x Tris buffered saline (TBS). 
Antigen retrieval was achieved by immersion in boiling 10mM sodium citrate buffer (pH 6) for 
10 mins followed by cooling at room temperature for 45 mins. Auto fluorescence was then 
quenched by 3x15 mins washes in sodium borohydride (Sigma-Aldrich) (0.5% w/v) in TBS 
followed by 3x5 mins detergent washing in TBS with 0.1% Tween 20 (Sigma-Aldrich) (TBST). 
Antigens were then blocked by application of 5% bovine serum albumin (BSA) (Sigma-Alrich) in 
TBST for 1 hr (250μL applied per slide) followed again by 3x5 mins detergent washes. Primary 
antibodies were applied at specified concentrations in 1% BSA (Sigma-Aldrich) in TBST (250μL 
applied per slide) and incubated overnight at 4°C in a moist environment. Following 3x5 mins 
detergent washing to remove unbound primary, appropriate secondary fluorophore 
antibodies were applied in 1% BSA (Sigma-Alrich) in TBST (250μL per slide) and incubated at 
room temperature for 2.5 hrs in a moist environment. Slides were then detergent washed prior 




to the application of anti-fade DAPI (Life Technology) and ethanol (TMK Packers) Surgipath™ 
coverslips (Leica).  
The formulation of two buffers used in the above protocol are outlined below; TBS Buffer 
(Table 2.14) and sodium citrate buffer (Table 2.15). 
Table 2.14 Formulation of 10x TBS Buffer  
10x TBS Buffer (pH 7.6) Concentration 
NaCl (Emsure, Darmstadt, Germany) 1.37Mol L-1 
KCl (Emsure) 208mMol L-1 
Tris hydrochloride (Sigma-Aldrich) 247mMol L-1 
 
Table 2.15 Formulation of Sodium Citrate Buffer 
Sodium Citrate Buffer (pH 6)  Concentration 
Trisodium citrate (Sigma-Aldrich)  1.39mMol L-1 
 
  




2.2.4.4 Haematoxylin and Eosin Staining  
4μm-thick FFPE sections of IH tissues were used for H&E staining using the protocol outlined 
in Table 2.16 prior to coverslipping with Surgipath™ coverslips (Leica).   
 
Table 2.16 Haematoxylin and Eosin Staining Protocol  
Solution Applied Incubation Period 
Xylene 5 mins 
Absolute alcohol 5 mins 
95% alcohol 5 mins 
Water washing  
Haematoxylin 5 mins 
Water wash  
Acid alcohol wash  
Eosin  5 mins 
Water wash   
95% alcohol 2 mins 
Absolute alcohol 5 mins 
Xylene 5 mins 
 




2.2.5 Image Analysis 
2.2.5.1 Cell and Tissue Culture 
Cell and tissue culture images were captured using a Leica DMIL LED Microscope (Leica) with 
a Leica DFC290 HD Camera (Leica). Software used for image acquisition was Leica Application 
Suite.  
2.2.5.2 Immunofluorescent Immunohistochemical and Immunocytochemical Staining 
IF IHC and ICC staining were captured using the Olympus FV1200 Confocal Microscope 
(Olympus) with Cellsens Software (Olympus). 
2.2.5.3 Bright Field Microscopy 
DAB IHC and H&E stained images were analysed using the Olympus BX53 Bright Field 
Microscope with an Olympus SC100 10.6 Megapixel Colour Camera (Olympus) with CellSens 
Software (Olympus). The eye piece on the microscope provided an additional 10x 
magnification. Throughout the thesis the original magnification referring to each micrograph 
is stated without the added 10x magnification of the eye piece.  
2.2.6 Genetic Analysis  
2.2.6.1 RNA Extraction from Tissues 
The harvesting of mRNA was performed for genetic analysis using a Qiagen RNeasy Mini Kit 
(Qiagen, Venlo, Netherlands). RNA was extracted from 6 samples of proliferating, involuting 
and involuted IH, each. 10mg tissue samples were homogenised in 350μL of RLT Buffer 
(Qiagen) + 1% β-mercaptoethanol (BioRad) using a plastic pestle and pipetted 7-10 times to 
shear DNA. Homogenates were centrifuged at 17,000xg for 3 mins and the supernatant was 
transferred to a clean tube. The lysate was mixed with 350μL 70% ethanol to promote binding 
of RNA to the RNeasy membrane (Qiagen), transferred to an RNeasy Mini spin column (Qiagen) 
and centrifuged at 8,000xg at room temperature for 15 secs and the flow-through discarded. 
The lysate was then washed three times initially with 700μL RW1 buffer (Qiagen), then 500μL 
RPE buffer (Qiagen)  and finally a further 500μL RPE buffer (Qiagen), centrifuged each time at 
8,000xg (15 secs, 15 secs, 2 mins respectively) and the flow-through discarded each time. The 
RNeasy spin column (Qiagen) was then placed in a new collection tube and centrifuged at 
17,000xg for 1 min to dry the membrane. Isolated RNA was then eluted from the membrane 
by applying 30μL of RNase-free water and centrifuging the RNeasy Mini Spin column (Qiagen) 




in a new elution tube at 8,000xg for 1 min. Total RNA yield was determined using a Nanodrop 
Spectrometer (Thermo Scientific) as per the manufacturer’s instructions and the samples 
stored at -80°C. 
2.2.6.2 Nanostring Genomic Evaluation 
RNA extracted from IH tissues was analysed offsite using fully automated NanoString 
Technology by New Zealand Genomics Limited (Dunedin, NZ). Briefly, the quantification of 
mRNA involves the hybridisation of report and capture probes with target mRNA to form a 
Target-Probe complex. Once purified to remove unbound probes, Target-Probe complexes 
were immobilised by binding of the capture proper region to an nCounter Cartridge. Using 
Digital Data acquisition the number of bound Target-Probe complexes was counted and the 
unique barcodes for each gene of interest was tabulated allowing relative expression levels of 
mRNA to be calculated. 
 
 




3 Chapter 3 Results: JAK-STAT Pathway in Infantile 
Haemangioma 
This chapter presents the findings of the investigations into the expression profile of signal 
transducer and activator of transcription (STAT) proteins within IH tissue. The presence of 
phosphorylated or activated forms of STAT1, STAT3 and STAT5 was investigated using DAB IHC 
and IF IHC staining as well as 1-DE WB. NanoString analysis was used to evaluate the mRNA 
expression levels for the STAT3 and STAT5 genes.  
STAT3 is the only member of the STAT family that has previously been demonstrated in IH 
tissue265, 348. It has been shown to be expressed within proliferating IH, localising to the nuclei 
of the ECs and mast cells348. Co-staining with PCNA (a proliferation marker) has revealed that 
STAT3 is predominantly localised in cells that are actively undergoing proliferation348. STAT1, 
STAT3 and STAT5 have also been implicated in the proliferation and differentiation of IH. 
Administration of VEGF in IHMSC culture enhances phosphorylation and nuclear localisation of 
STAT1, whilst addition of IFN-α2b induces these effects on all three STAT proteins265.  
Both CD34 and GLUT-1 are well documented to mark the capillary endothelium in all stages of 
IH. Where multiple results are available that giving the clearest demarcation of capillary 
endothelium is presented.  
3.1 STAT1 in Infantile Haemangioma STAT1 in Infantile Haemangioma  
DAB IHC staining (Figs 3.1-4) revealed the highest expression of pSTAT1 in proliferating IH (Fig. 
3.1A). Both DAB (Figs 3.2-4) and IF (Fig. 3.1) IHC staining demonstrated the absence of pSTAT1 
in involuted lesions. Both staining techniques demonstrated that pSTAT1 was expressed in 
both the cytoplasm (Fig. 3.2B) and the nuclei (Fig. 3.2 B&D) of the interstitial cells (Fig. 3.3 C&F 
and Fig. 3.4C) and the pericytes (Fig. 3.4C). DAB IHC staining showed that pSTAT1 was focally 
expressed and was localised to discrete areas of the lesion (Fig. 3.3 C&F). Co-staining with SMA 
(Fig. 3.4), however, showed that the expression of pSTAT1 was minimal on the endothelium 
(Fig. 3.4 C&E). 
1-DE WB, as a semi-quantitative analysis of pSTAT1 in IH tissue (Fig. 3.5), revealed that whilst 
present in all phases of IH, pSTAT1 expression was highest in the proliferative phase. 




NanoString data was not available for mRNA levels of STAT1 in IH, thus conclusions could not 
be drawn as to the mRNA transcription levels of the STAT1 gene within IH.   




3.1.1 pSTAT1 Expression in Infantile Haemangioma by Immunohistochemical 
Staining 
3.1.1.1 pSTAT1 Expression in Infantile Haemangioma by IF Immunohistochemical taining  
 
 
Figure 3-1. Representative IF IHC stained images of pSTAT1 (A&B, red), CD34 (A, green) and 
SMA (B, green) in proliferating (A) and involuted (B) IH. Cell nuclei were counter-stained with 
4', 6-diamidino-2-phenylindole (DAPI) (A&B, blue). A small quantity of nuclear staining of 
pSTAT1 was present in cells in the interstitium of proliferating (A), but not involuted (B) IH. 
Original magnification: 40X. 
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Figure 3-2. Representative DAB IHC stained images of pSTAT1 (A-F, brown) of proliferating 
(A&B), involuting (C&D) and involuted (E&F) IH. Cell nuclei were stained with haematoxylin 
(A-F, blue). Highest expression of pSTAT1 was observed in proliferating IH (A&B) with both 
nuclear and cytoplasmic localisation to the endothelial (B, arrowhead) and pericyte (B, arrow) 
layers. Expression of pSTAT1 was reduced with almost exclusive nuclear localisation the 
involuting (C&D) and was absent in the involuted (E&F) IH. Original magnifications:  10X (A, 










3.1.1.3 pSTAT1 and GLUT-1 Expression in Infantile Haemangioma by DAB 
Immunohistochemical Staining 
Figure 3-3. Representative DAB IHC stained images of pSTAT1 (A-F, brown) and GLUT-1 (A-F, 
red) of proliferating (A, C&E) and involuted (B, D&F) IH. Cell nuclei were stained with 
haematoxylin (A-F, blue). pSTAT1 was localised to the interstitial cells, predominantly in the 
nuclei and minimally in the cytoplasm, in proliferating IH (A, C&E). pSTAT1 was not expressed 
by the GLUT-1+ microvessels and was absent in involuted IH (D&F). Original magnifications: 
10x (A&B), 40X (C-F). 















3.1.1.4 pSTAT1 and SMA Expression in Infantile Haemangioma by DAB Immunohistochemical 
Staining  
Figure 3-4. Representative DAB IHC stained images of pSTAT1 (A-F, brown) and SMA (A-F, 
red) in proliferating (A, C&E) and involuted (B, D&F) IH. Cell nuclei were stained with 
haematoxylin (A-F, blue). pSTAT1 was focally expressed in proliferating IH (A&C), however, 
this was not consistently observed in morphologically similar regions of the lesion (E). pSTAT1 
was expressed in both the cytoplasm and cell nuclei in the pericyte layer (C, arrows) and 
interstitium (C, arrow heads) but not the endothelial cells (C). Original magnifications: 10X 



















3.1.2 pSTAT1 in Infantile Haemangioma by Western Blotting 




(First lysates)  
 
β-Actin  
42 kDA  
 
         Proliferating IH (x3)            Involuting IH (x3)               Involuted IH (x3)  
Figure 3-5. Western Blot demonstrating the expression of pSTAT1 at 91kDA. Protein was 
extracted from proliferating (n=3), involuting (n=3) and Involuted (n=3) IH.  An intense band 
of pSTAT1 was seen at the expected size of 91 kDA in 2 of the 3 proliferating lesions. Minimal 
to non-specific staining was present in 3 involuting lesions whilst 2 of the 3 involuted lesions 
demonstrated a specific band for pSTAT1 at the expected size. β-actin re-probe revealed 












3.2 STAT3 in Infantile Haemangioma  
IF IHC staining demonstrated abundant cytoplasmic and nuclear staining of pSTAT3 in 
proliferating IH (Fig. 3.6 A) but was absent in involuted lesions (Fig. 3.6 B). Conversely DAB IHC 
staining (Figs 3.7-9) showed that whilst pSTAT3 expression tapered with involution of the 
tumour (Fig. 3.2), it was expressed in all three phases of IH development. More specifically 
both cytoplasmic (Fig. 3.2 B) and nuclear (Figs. 3.8 C&E and 3.9 C&E) staining were evident in 
proliferating IH, with only nuclear localisation demonstrated in involuted lesions (Figs. 3.7F and 
3.9 D&F). In proliferating IH, pSTAT3 was widely expressed (Fig 3.7 A&B) in the pericyte layer 
(Fig 3.7F), the interstitial cells (Fig. 3.8 C&E) and the endothelial layer (Fig. 3.8C). pSTAT3 
expression was predominantly localised to the endothelium in involuting (Fig. 3.7D) and 
involuted (Fig. 3.8F) IH. pSTAT3 expression was predominantly localised to the endothelium 
and pericytes in involuting (Fig. 3.7D) and endothelial nuclei of involuted (Fig. 3.8F) IH.  
1-DE WB revealed the presence of pSTAT3 (Fig. 3.10) in all phases of IH, with the expression 
levels not significantly different between the phases.  
NanoString analysis confirmed transcription of the STAT3 gene in both proliferating and 
involuted IH (Fig. 3. 11) and, there was no statistical quantitative difference between the two 
phases. 
  




3.2.1 pSTAT3 Protein Expression in Infantile Haemangioma by 
Immunohistochemical Staining 
3.2.1.1 pSTAT3 Expression in Infantile Haemangioma by IF Immunohistochemical Staining 
  
Figure 3-6. Representative IF IHC stained images of pSTAT3 (A&B, red) and CD34 (A&B, green) 
of proliferating (A) and involuted (B) IH. Cell nuclei were counterstained with DAPI (A&B, 
blue). pSTAT3 was widely expressed in the cytoplasm of proliferating IH with predominant 
cytoplasmic localisation (A, arrowheads) and some nuclear staining (A, arrow) but was absent 











3.2.1.2 pSTAT3 Expression in Infantile Haemangioma by DAB Immunohistochemical Staining 
  
    
  
Figure 3-7. Representative DAB IHC stained images of pSTAT3 (A-F, brown) of proliferating 
(A&B), involuting (C&D) and involuted (E&F) IH. Cell nuclei were stained with haematoxylin 
(A-F, blue). pSTAT3 was expressed in all three phases of IH with the highest expression in the 
proliferating lesions (A&B) localising to the cytoplasm (B, arrow heads) and nuclei (B, arrows). 
pSTAT3 was widely expressed in involuting IH (C) in both the endothelial cells and pericytes 
(D). pSTAT3 expression was reduced in involuted IH, predominately localising to the nuclei of 













3.2.1.3 pSTAT3 and GLUT-1 Expression in Infantile Haemangioma by DAB 
Immunohistochemical Staining 
Figure 3-8. Representative DAB IHC stained images of pSTAT3 (A-F, brown) and GLUT-1 (A-F, 
red) of proliferating (A, C&E), and involuted (B, D&F) IH. Cell nuclei were stained with 
haematoxylin (A-F, blue). pSTAT3 was widely expressed in both proliferating (A) and involuted 
(B) IH localising to the nuclei predominantly of the endothelial cells (C&E, arrow heads), and 
to a less extent, the pericytes (C&E, arrows) and interstitial cells in proliferating IH (C&E). 
pSTAT3 expression was reduced In involuted IH, also exclusively localised to the nuclei, mainly 
of the interstitial cells and pericytes rather than the endothelium (D&F).  Original 
magnifications: 10X (A&B), 40X (C-F).  
  
  
    
 













3.2.1.4 pSTAT3 and SMA Expression in Infantile Haemangioma by DAB Immunohistochemical 
Staining 
Figure 3-9. Representative DAB IHC stained images of pSTAT3 (A-F, brown) and SMA (A-F, 
red) of proliferating (A, C&E) and involuted (B, D&F) IH. Cell nuclei were stained with 
haematoxylin (A-F, blue). There was highest pSTAT3 staining in proliferating (A, C&E) IH with 
reduced expression in the involuted (B, D&F) lesion. pSTAT3 was localised to the pericytes 
which stained positively for SMA (C&E, arrows). Positive nuclear staining was seen in the 
endothelial cells (C&E, arrow heads) but not the pericyte layer which stained positively for 
SMA (C&E, red). Minimal expression of pSTAT3 was detected in involuted lesions. Original 















3.2.2 pSTAT3 Expression in Infantile Haemangioma by Western Blotting 




(First lysates)  
 
β-Actin  
42 kDA  
 
       Proliferating IH (x3)         Involuting IH (x3)                     Involuted IH (x3)  
Figure 3-10. Western Blotting demonstrating the expression of pSTAT3 at 86kDA. Protein 
was extracted from proliferating (n=3), involuting (n=3) and involuted (n=3) IH.  A band of 
pSTAT3 at the expected size of 86kDA is visible in all three phases of IH. An intense band 
was seen in 1 of 3 proliferating lesions, with a faint band present in the other two samples. 
2 of the 3 cases of each of the involuting and involuted IH lesions revealed a faint band at 
the expected size. β-actin re-probe reveals that protein loading was approximately equal 
in all lanes other than lane 7 (involuting IH) which indicates a very low level and lane 9 
which exhibited a more intense band.  
  




3.3 STAT3 and STAT5 mRNA Levels in Infantile Haemangioma  
Table 3.1 Nanostring Analysis Data: Relative Copy numbers of mRNA in IH  
 
 
Figure 3-11. STAT3 and STAT5 mRNA levels in IH tissues. NanoString nCounter Gene Expression 
assay with specific probes for STAT3 and STAT5 genes was performed using mRNA extracted 
from proliferating (n=6) and involuted (n=6) IH samples. Data was analysed using the Student 
t-test (n.s. = no significance) and presented as mean ± standard error. Comparison of 

























STAT3 and STAT5 mRNA in IH 
IH Involuted IH Proliferating
Proliferating Infantile Haemangioma  
 Sample 1 Sample 2 Sample 3 Sample 4 Sample 5  Sample 6 
STAT3 mRNA 8736.47 5547.37 4583.77 4719.17 6112.62 6927.81 
STAT5 mRNA  327.44 270.44 291.76 742.9 175.01  
Involuted Infantile Haemangioma  
 Sample 1 Sample 2 Sample 3 Sample 4 Sample 5  Sample 6 
STAT3 mRNA 8499.06 6363.67 7223.12 7015.67 5571.87 8832.69 
STAT5 mRNA  2353.92 633.02 2603.47 585.35 619.63 297.96 




Whilst the difference between the mRNA levels in proliferating and involuted IH is not 
statistically significant, a trend was observed for both STAT3 and STAT5 indicating that mRNA 
translation may increase as IH involutes. This technique would benefit from an increased 
number of IH samples to achieve statistical significance. The levels of STAT3 mRNA were 
notably greater than STAT5 in equivalent lesions.  
  




3.4 STAT5 in Infantile Haemangioma  
IHC staining (Figs 3.12-3.15) revealed that whilst pSTAT5 expression was minimal, it peaked 
during the proliferative phase of IH (Figs. 3.13 A&B and 3.14 A, C&E) with both DAB and IF IHC 
demonstrating its absence in involuted lesions (Fig. 3.12 B). DAB IHC staining showed the 
presence of pSTAT5 predominantly on the endothelium (Fig. 3.14 A, C&E), supported by IF IHC 
staining which demonstrated nuclear expression of pSTAT5 in both the endothelium and 
interstitium (Fig.3.12A). Co-staining of pSTAT5 and SMA showed positive nuclear staining of 
pSTAT5 by a small proportion of pericytes that stained positively for SMA in proliferating IH 
(Fig.3.15. E).  
WB for pSTAT5 in IH tissue revealed minimal expression in all phases of IH (Fig. 3.16). Semi-
quantitation with WB for total STAT5 in IH tissue (Fig. 3.17) confirmed the presence of STAT5 
in all phases of IH, however, the anti-STAT5 antibody used, detected both phosphorylated and 
non-phosphorylated forms of this protein.   
NanoString data (Fig. 3.11) confirmed transcription of STAT5 at the gene level in both 
proliferating and involuted IH. STAT5 mRNA expression was lower than that of STAT3 mRNA in 
both proliferating and involuted IH, however, the difference was not statistically significant. 
  




3.4.1 pSTAT5 Expression in Infantile Haemangioma by Immunohistochemical 
Staining 
3.4.1.1 pSTAT5 Expression in Infantile Haemangioma by IF Immunohistochemical Staining 
  
Figure 3-12. Representative IF IHC images of pSTAT5 (A&B, red) and GLUT-1 (A&B, green) of 
proliferating (A), and involuted (B) IH. Cell nuclei were counter-stained with DAPI (A&B, blue). 
pSTAT5 was expressed in proliferating (A) and is absent in involuted lesions (B). Co-staining 
with the endothelial marker, GLUT-1 (green), revealed few cells expressing both GLUT-1 and 
pSTAT5, whilst pSTAT5 staining was localised mainly to the interstitial cells and pericytes 
distinct from the capillary endothelium. Original magnification: 40X.  
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3.4.1.2 pSTAT5 Expression in Infantile Haemangioma by DAB Immunohistochemical Staining 
  
   
  
Figure 3-13. Representative DAB IHC stained images of pSTAT5 (A-F, brown) of proliferating 
(A&B), involuting (C&D) and involuted (E&F) IH. Cell nuclei were stained with haematoxylin 
(A-F, blue). pSTAT5 expression was highest in the proliferating (A&B) and was absent in the 
involuted (E&F) IH. pSTAT5 was localised predominantly to the nuclei of endothelial cells 













3.4.1.3 pSTAT5 and GLUT-1 Expression in Infantile Haemangioma by DAB 
Immunohistochemical Staining 
Figure 3-14. Representative DAB IHC stained images of pSTAT5 (A-F, brown) and GLUT-1 (A-
F, red) of proliferating (A, C&E) and involuted (B, D&F) IH. Cell nuclei were stained with 
haematoxylin (A-F, blue). pSTAT5 was expressed minimally in proliferating (A, C&E) and is 
absent in involuted (B, D&F) IH, predominantly localised to the nuclei of endothelial cells (A, 
















3.4.1.4 pSTAT5 and SMA Expression in Infantile Haemangioma by DAB Immunohistochemical 
Staining 
Figure 3-15. Representative DAB IHC stained images of pSTAT1 (A-F, brown) and SMA (A-F, red) 
of proliferating (A, C&E) and involuted (B, D&F) IH. Cell nuclei were stained with haematoxylin 
(A-F, blue). When co-stained with SMA it was difficult to distinguish positive pSTAT5 staining in 
















3.4.2 pSTAT5 Expression in Infantile Haemangioma by Western Blotting 






42 kDA  
 
       Proliferating IH (x3)         Involuting IH (x3)                     Involuted IH (x3)  
Figure 3-16. Western Blotting demonstrating the expression of pSTAT5 at 90kDA. Protein was 
extracted from proliferating (n=3), involuting (n=3) and involuted (n=3) IH.  An intense band 
was seen at the expected size of 90kDA in 1 of the 3 proliferating lesions with a faint protein 
band present in equal proportion in all other lanes. β-actin re-probe revealed that protein 
loading was approximately equal in all lanes other than lane 1 which exhibited a more intense 
band.  
3.4.3 Total STAT5 Expression in Infantile Haemangioma by Western Blotting 






42 kDA  
 
       Proliferating IH (x3)         Involuting IH (x3)                     Involuted IH (x3)  
Figure 3-17. Western Blotting demonstrating expression of total STAT5 (both phosphorylated 
and un-phosphorylated) at 90kDA. Protein was extracted from proliferating (n=3), involuting 
(n=3) and involuted (n=3) IH.  A faint protein band was seen at the expected size of 90kDa in 3 
of the 3 proliferating and 2 of the 3 involuting lesions and was absent in all involuted cases. β-
actin re-probe reveals that protein loading was approximately equal in all lanes other than lane 
7 which lacked β-actin.  
  




4. Chapter 4 Results: Infantile Haemangioma Explant Culture and 
Differentiation of IHEDCs 
This chapter presents the findings of IH explant culture and differentiation of IHEDCs in culture. 
The effect of administration of the SCFAs, butyric acid and propionic acid, at a range of 
concentrations to IHEDCs in culture was investigated using cell counting and light microscopy 
techniques.  
IH explant tissue was cultured using a technique first described by Tan et al23. Briefly 1mm3 
pieces of IH explants were embedded between two layers of Matrigel (Corning) and cultured 
in RMPI media and incubated at 37°C at 80% RH, and 5% CO2. The media was changed every 
3-4 days. Cells emanate from the IH explants within days of culture23. These IHEDCs can been 
differentiated down the mesenchymal cell lines to osteoblasts and adipocytes19. IHEDCs have 
also been shown to form blast-like structures upon re-plating, with blast density enhanced by 
the addition of ATII49. This is the first study to investigate the effects of the addition of SCFAs 
to IHEDCs in culture.  
  




4.1 In Vitro Culture of Infantile Haemangioma Explant Tissue  
IHEDCs were seen to arise from IH tissue explant within days of culture and were maintained 
up to 3 months in culture (Fig. 4.1 D). The morphology of IHEDCs was heterogeneous, 
consisting uniformly circular cells (Fig. 4.1 B&C) and those with a fibroblast-like morphology 
(Fig. 4.1 A, C&D) arising from the IH explants in culture.  
Figure 4-1. IHEDCs arising from proliferating IH explants in culture. IHEDCs arising from the 
periphery of proliferating IH explants in culture at 24 (A&B), 35 (C) and 72 (D) days. Some cells 
were uniformly circular (arrow heads) and others had a fibroblast-like morphology (arrows) 















4.2 IHEDCs in Culture with Short Chain Fatty Acids  
Following IH explant culture, IHEDCs were harvested using a Dispase protocol and re-plated in 
Matrigel at a density of 50,000 live cells per well, in a 24-well plate. Cells were then cultured in 
a range of concentrations of either butyric acid or propionic acid. The proliferative effects of 
the SCFAs on the IHEDCs in culture was evaluated using light microscopy (Figs. 4.2-3), and 
counting of viable cells using a Countess Cell Counter (Invitrogen) (Figs. 4.5-7) and the 
induction of erythroid differentiation was evaluated using IF ICC (Figure 4.4).  
Globin inducing effects of SCFAs have been widely investigated and butyrate has been reported 
to increase γ-mRNA levels318, 319, 321 and HbF counts318-320  in both in vitro human cell culture319-
321 and in vivo human318 and baboon319 studies. Boosalis et al.319 report that the application of 
butyric acid results in an increase in the expression of the growth promoting genes c-myc and 
c-myb resulting from butyric acid induced prolonged STAT5 activation in MEL cell culture.  
Due to the time available to complete this BMedSci project, a functional study was conducted 
with cell counting data gathered from culture of IHEDCs from fresh IH tissues of a single 
patient, as a pilot study.  
4.3 Light Microscopy of IHEDCs in Culture with Administration of Short 
Chain Fatty Acids  
Images of IHEDCs in culture with the administration of SCFAs were captured with a light 
microscope at 24, 48 and 72 hrs (Fig. 4.3). Under all experimental conditions the cells exhibited 
greater proliferation compared with control samples with the omission of the cytokines. The 
proliferative effect on the IHEDCs was greatest in the first 24 hrs following administration of 
butyric acid or propionic acid, as evidenced by the marked increase in blast density for all 
experimental conditions, compared with control samples at this time point. No increase in blast 
density was observed at 48 and 72 hr time points, under any of the culture conditions.  
The most significant induction of IHEDC proliferation occurred in the presence of 0.1mM 
butyric acid, whilst higher concentrations of propionic acid was required in to achieve a similar 
effect. 
 




Figure 4-2. Light microscopy images of IHEDCs cultured in the presence of butyric acid (central 2 columns) and propionic acid (2 columns on the 
right) at 24 (top row), 48 (middle row) and 72 (bottom row) hrs showing increased blast density within the first 24 hrs following administration of 
butyric acid and propionic acid in all culture conditions, compared to negative control samples (left column). At 24 hrs, butyric acid at 0.1mM had 
an equivalent proliferative effect to DMSO at 0.05M as positive control (second column from the left). No increase in blast density was observed 
beyond 24 hrs. Original magnification: 40x. 
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4.4 Characterisation of IHEDCs in Culture Following Administration of 
Propionic Acid   
Light microscopy of IHEDCs cultured in the presence of propionic acid revealed a change in 
IHEDC morphology. Following harvest from tissue culture and re-plating in Matrigel, IHEDCs 
formed blast-like structures (Fig. 4.3A), consistent with previous report49. After 72 hrs in 
culture with 0.1mM propionic acid, blast-structures formed distinct singular, bi-concave 
structures (Fig. 4.3B). Further characterisation of these IHEDC-derived structures was 
performed by IF ICC staining using an antibody to the erythrocyte-specific marker, α-
glycophorin A (Fig. 4.4). The presence of immunofluorescence to α-glycophorin A and the 
absence of nuclear marker DAPI confirmed the presence of enucleated erythrocytes. These 
erythrocytes are 2-4μm compared with normal human erythrocytes that are 6-8μm in size.  




Figure 4-4. IF ICC staining of singular, bi-concave structures shown in Figure 4.3B harvested following 
72 hrs in culture using an α-glycophorin A antibody (green) with absence of nuclear marker, DAPI (blue) 








4.5 Quantitation of the Proliferative Effect of Short Chain Fatty Acids 
on IHEDCs in Culture  
Quantitative evaluation of the proliferative effect of butyric acid and propionic acid was 
performed on cells harvested following culture under experimental and control conditions by 
counting of the live cells (Figs. 4.5-7). A Countess Cell Counter (Invitrogen) was used for 
automated counting of viable cells confirmed by trypan blue dye.  
Following 24 hrs of IHDEC in culture (Fig. 4.5) under all cytokine conditions, proliferation in 
RPMI media was enhanced by the presence of iron. Proliferation was further increased when 
the IHDECs were cultured in MCDB media which contains iron as well as low concentration of 
copper and other additional compounds. A dose-response relationship was observed by the 
administration of butyric acid when IHDECs were cultured in different media. However, this 
was not reproduced with the administration of propionic acid to the culture. After 24 hrs in 
culture, the proliferative effect of butyric acid was significantly higher than that of propionic 
acid under all three experimental concentrations. The effect of butyric acid on the IHDECs 
cultured in MCDB was higher than that of butyric acid in either iron-enriched or iron-depleted 
RPMI media. Conversely, the propionic acid had an additive effect with iron-enriched RPMI 
media. Cell counts were significantly higher following IHDECs cultured in iron-enriched RPMI 
compared with those cultured in iron-deficient RPMI media, at all concentrations of propionic 
acid. Cell counts following culture of IHEDCs in MCDB at all concentrations of butyric acid or 
propionic acids exceeded that those cultured in DMSO at 0.05M in MCDB (positive control), 
after 24 hrs. Cell counts following culture of IHDECs RPMI media and RPMI with addition of 
iron for all concentrations of butyric acid exceeded that of DMSO at 0.05M in RPMI (positive 
control). However, for IHDECs cultured with the administration of propionic acid this effect 
was observed only by the addition of iron to the RPMI media, further highlighting the possible 
additive effect of iron and propionic acid.  
The dose-response relationships were lost at 48 hrs and it was difficult to infer any pattern 
from the cell counting data (Fig. 4.6). At 48 hrs cell counts for all experimental conditions in 
MCDB media were significantly lower. The decrease in cell counts was not observed in either 
the negative or positive controls. In both the positive and negative controls the greatest cell 
counts were observed at 48 hrs compared with cultures at 24 (Fig. 4.5) or 72 (Fig. 4.7) hrs.  




By 72 hrs the iron-enriched RPMI media (RPMI + Fe) was most successful at maintaining cell 
numbers in the presence of the cytokines (Fig. 4.7).   




4.5.1 Viable Cell Counts following IHEDCs Cultured in SCFAs at 24 Hours 
 
Figure 4-5 Viable cells harvested following IHEDCs cultured in a range of concentrations of 
butyric acid or propionic acid at 24 hrs. Cells were harvested following culture with 
administration of  butyric acid or propionic acid at 0.05mM, 0.1mM and 1mM, omission of the 
cytokines (negative control) and addition of DMSO at 0.05M (positive control). For each culture 
condition cells were cultured in RPMI media alone, RPMI media-enriched with 1μM iron and 






































IHEDC Culture at 24 hours 
RPMI RPMI + Fe MCDB




4.5.2 Viable Cell Counts following IHEDCs Cultured in SCFAs at 48 Hours 
 
 
Figure 4-6. Viable cells harvested following IHEDCs cultured in a range of concentrations of 
butyric acid or propionic acid at 48 hrs. Cells were harvested following culture following 
administration of butyric acid or propionic acid at 0.05mM, 0.1mM and 1mM, omission of the 
cytokines (negative control) and addition of DMSO at 0.05M (positive control).  For each 
cytokine condition cells were cultured in RPMI media alone, RPMI media-enriched with iron 







































IHEDC Culture at 48 hours 
RPMI RPMI + Fe MCDB




4.5.3 Viable Cell Counts following IHEDCs Cultured in SCFAs at 72 Hours 
 
 
Figure 4-7. Viable cells harvested following IHEDCs cultured in a range of concentrations of 
butyric acid or propionic acid at 72 hrs. Cells were harvested following culture with 
administration of butyric acid and propionic acid at 0.05mM, 0.1mM and 1mM, omission of 
the cytokines (negative control) and addition of DMSO at 0.05M (positive control).  For each 
cytokine condition cells were cultured in RPMI media alone, RPM94I media-enriched with iron 





































IHEDC Culture at 72 hours
RPMI RPMI + Fe MCDB




5 Chapter 5 Discussion 
5.1 Interpretation of the Findings of This Study  
This study aimed to investigate: (1) the expression and activity of the components of the JAK-
STAT pathway in IH; (2) the haemogenic potential of IH in vitro; and (3) the effects of short 
chain fatty acids (SCFAs), to induce erythroid differentiation of IH explant-derived cells 
(IHEDCs) in the culture. 
Protein and genomic data reveal that STATs 1, 3 and 5 are activated in IH, particularly in the 
proliferative phase, with expression tapering as the lesion involutes. Expression of pSTAT1 in 
the endothelium is minimal in the proliferative phase, whilst both nuclear and cytoplasmic 
expression is observed in the pericyte layer and the interstitial cells. pSTAT1 is not significantly 
expressed in involuted IH and is only demonstrated by 1DE-WB in involuted lesions. pSTAT3 is 
expressed most abundantly in the endothelial, pericyte and interstitial populations with both 
nuclear and cytoplasmic localisation in proliferating IH. The expression of pSTAT3 tapers with 
involution of IH, and is limited to the nuclei of ECs in involuted lesions. pSTAT5 is the least 
abundantly expressed of the STAT proteins in IH using all methods of investigation 
demonstrating its absence in the involuted IH. Whilst expressed in all cell types within IH, IF 
IHC staining demonstrates that it is predominantly localised to ECs during the proliferative 
phase.  
NanoString analysis for both STAT3 and STAT5 genes revealed a reverse trend for mRNA 
transcription to that of STAT activation demonstrated by IHC staining and 1DE-WB. Whilst the 
difference in the mRNA abundance between proliferating and involuted lesions for both of 
these STAT transcripts was not statistically significant, there is a trend of increased expression 
as IH involutes. The discrepancy between the translational activity of the gene and the 
presence of the activated protein may be due to degradation of the protein in the involuted IH 
tissues, potentially due to the secretion of proteases349, 350. Furthermore small sample size and 
morphological heterogeneity within IH tissue samples may account for the statistically 
insignificant difference in the mRNA abundance between proliferating and involuted lesions.  
IHEDCs generated blast-like structures in culture, which is consistent with previous reports 
showing spontaneous differentiation into erythrocytes after five months in culture49. In this 




study, administration of butyric acid or propionic acid leads to increased proliferation of these 
blast-like structures which differentiate into enucleated erythrocytes that express glycophorin 
A, within 72 hours in culture.  
5.1.1 pSTAT1 
In cancer, pSTAT1 is known to exhibit a tumour suppressor function351-355, growth inhibition356-
368, and is a positive prognostic marker369. It would be reasonable to expect that in inducing a 
tumour suppressor function, pSTAT1 expression would correlate with reduced proliferation. 
Down-regulation of pSTAT1 as IH involutes, indicates that its expression is aligned with 
haematopoietic stem cell activity, rather than tumour suppression.  
Activation of STAT1 within IH is likely to be related to the STAT-1 dependent signalling of IFN-
α (a type I IFN) and IFN-γ (a type II IFN) which are secreted by leukocytes including 
macrophages370. IFN-α, through the activation of STAT1, stimulates dormant HSCs to enter the 
cell cycle212 with the IFN regulatory factor 2 (IRF2) opposing this action, and consequently, 
preserving HSC inactivity with resultant maintenance of the stem cell pool255. IFN-γ, also 
dependent on STAT1 signalling213, 260, promotes expansion of HSCs213, 214 and myeloid 
progenitors215, 259-262. It is suggested that whilst IFN-1 promotes the phosphorylation of STAT1 
resulting in entry into the cell cycle and consequent proliferation and differentiation212, 255, IFN-
type-II signalling through activated STAT1 may result in cell apoptosis258. IFN regulatory factor-
2 (IRF2) is known to regulate the transcription of IFNs371.  
In the clinical context, IFN-α2a (an IFN-α derivative), has been used as a second-line 
pharmacological treatment for steroid-resistant IH372-376 with a response rate of 90%. Analysis 
of proliferating lesions following IFN-α2a treatment reveals the presence of apoptotic EC 
nuclei, consistent with those observed in involuting IH, but not seen in untreated proliferating 
IH377.  
Exhaustion and consequent apoptosis of HSCs as a result of excessive signalling of IFN-α212, 255, 
263 and IFN-γ258, 264 may explain the IFN-α2a induced EC apoptosis.  
Preliminary data from DAB IHC staining (Fig. 5.1) and matrix-assisted laser 
desorption/ionisation (MALDI) - time-of-flight (TOF) mass spectrometry analysis, suggests the 
IFN regulatory factor-2 (IRF2) is expressed in proliferating IH. It is interesting to speculate that 
the activity within IRF2 may explain why the IH stem cell pool does not become exhausted as 




seen with excessive STAT1 signalling in other context212, 255, instead facilitating the asymmetric 
division that is required for stem cell maintenance.  
  
Figure 5-1 DAB IHC stained images of IFR-2 (A&B, brown) in proliferating IH (A), and positive 
control colon tissue (B). Cell nuclei were stained with haematoxylin (A&B, blue). IFR-2 is 
expressed in the nuclei of proliferating IH endothelial cells and pericyte cells relating to its 
transcription factor function. Original magnifications:  10X (A, C&E), 40X (B, D&F). 
Mast cells378, 379 and macrophages380 within IH maybe a potential local origin of these IFNs. The 
highest expression of pSTAT1 within proliferating IH links to its role as a promoter of HSC 
activity. As the lesion involutes and stem cells responsible for the aberrant proliferation, 
terminally differentiate (typically to adipocytes), the expression of pSTAT1 diminishes and is 
ultimately undetectable in involuted lesions. An absence of pSTAT1 in involuted IH reflects the 
concept that stem cells within the lH have terminally differentiated with the haematopoietic 
activity also ceased.  
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pSTAT3 is the most abundantly expressed of the STAT proteins in IH in both ECs and the 
pericyte layer. Whilst its expression tapers as the lesion involutes, there remains a considerable 
quantity of activated STAT3 within involuted lesions. This suggests that STAT3 plays a distinct 
temporal role in the biology of IH in that the local microenvironment changes as the lesion 
involutes.  
Similar to pSTAT1, the role for pSTAT3 within proliferating IH reflects its function in stem cell 
biology, specifically in stem cell maintenance. Maintenance of hESCs in a pluripotent state is 
dependent on an IL-6 family member 284, LIF281-283, with STAT3 being a critical element in this 
pathway284, 287, 288. Thus, the expression of pSTAT3 in the proliferative phase of IH correlates 
with the presence of MSCs within the lesion18, 19, 21, 62, 75. It is also interesting to note that 
macrophages, a source of LIF secretion, are known to be present within IH380.  
Itinteang et al.19 have demonstrated the expression of neural crest62 and mesenchymal19 
markers and Pref-119 (an inhibitor of mesenchymal differentiation) on the endothelium of 
proliferating IH. Conversely, Yuan et al.21 suggest that stem cells within IH are located in the 
perivascular layer. Pericytes themselves are known to retain a high level of plasticity with the 
capability of multi-lineage mesenchymal differentiation381-383 and consequently it is proposed 
that pericytes are “connected” to the MSCs in some way384, 385. The demonstration of MSCs 
beyond the endothelium of IH and the multi-lineage potential of the pericytes correlates with 
the widespread expression of the stem cell-related pSTAT3 throughout the proliferative phase 
of IH.  
A role for the RAS in the biology of IH has been demonstrated by the expression of the 
components of the RAS in IH49 and clinical demonstration of accelerated involution of IH 
induced by RAS modulators38-44 54. It is thus important to note that ATII, a component of the 
RAS, has been shown to induce STAT3 phosphorylation240 including the resultant vascular SMC 
proliferation386, and that deletion of either STAT1 or STAT3 abolishes this effect387. It is 
reasonable to propose that widespread STAT3 activation in IH may reflect RAS signalling. 
Increased proliferation of blast-like structures following administration of ATII to IHEDCs in 
vitro49 may occur down-stream to STAT3 phosphorylation. Likewise, the accelerated involution 




of IH induced by modulators of the RAS, β-blockers38-44 and ACE inhibitor54, may occur through 
reduced activation of STAT3 and consequent loss of stem cell maintenance.  
In the context of cancer, glioblastoma stem cells (GSC) have been demonstrated to generate 
vascular pericytes to support vessel function and tumour growth388. The self-renewal of these 
GSCs and there tumorigencitiy, including pericyte differentiation is demonstrated to be 
dependent on the signalling of pSTAT3272, 290, 389. Thus it is appropriate to infer that the role of 
STAT3, demonstrated in the present study to be activated in involuted IH, may relate to a role 
in the formation of pericytes.  
5.1.3 pSTAT5 
Of the three STAT proteins, pSTAT5 is expressed in the lowest quantity. IHC staining reveals 
nuclear localisation of pSTAT5 to ECs, pericytes and interstitial cells in proliferating IH and a 
complete absence in involuted lesions. As pSTAT5 is essential for primitive haematopoiesis228, 
294, 300, 305-307 the presence of pSTAT5 in proliferating IH provides further evidence of the 
presence of a functional HE within proliferating IH.  
pSTAT5 is known to signal down-stream of the EPOR295-297. As EPOR is expressed on both the 
endothelium of IH and the placental trophoblast villous cells75, 390 (the proposed cellular origin 
of IH75, 390), expression of pSTAT5 on the endothelium of IH is not unexpected. Furthermore 
EPO administration for (anaemia of prematurity) is a risk factor for IH development31, 
highlighting the role of EPOR signalling and erythropoiesis in proliferating IH. As EPOR has not 
been identified beyond the endothelium of IH20, STAT5 activation in the pericyte layer and the 
interstitial populations is, however, unexpected. As the mesenchyme underlying a HE has been 
regarded essential in the development of an appropriate microenvironment for 
haematopoiesis, diffuse pSTAT5 expression may support this concept. Conversely unexpected 
pSTAT5 expression may simply reflect the high level of plasticity in the primitive cell 
populations which comprise IH.  
5.1.4 Haematopoietic Potential of Infantile Haemangioma Explant-Derived Cells  
IHEDCs have previously been differentiated toward adipocyte and osteoblast lineages19. 
However, despite the evidence for the inherent haematopoietic activity in IH16, 20, this is the 
first instance in which IHEDCs have been differentiated down a haematopoietic lineage. That 
formation of erythrocytes following five months of IH explant culture, a duration that far 




exceeds the normal lifespan of erythrocyte in vivo391, confirms their in vitro origin. 
Consequently, active haematopoiesis within IH is further supported here by the spontaneous 
differentiation of IHEDCs into enucleated erythrocytes that express glycophorin-A, through the 
formation of a blast-like intermediate.  
5.1.4.1 Development of Microcytic Erythrocytes with the Present Model  
One of the most significant observations in this functional pilot study is the generation of 
microcytic erythrocytes when IHEDCs are cultured in iron-depleted media, further supporting 
IH as a useful human model for haematopoiesis. Iron is well known as an essential factor in the 
production of haemoglobin, with its deficiency resulting in microcytic anaemia of significantly 
reduced erythrocyte volume392. At 2-4μM, IHEDC-derived erythrocytes generated in the 
present study are significantly smaller than the expected 6-8μM size of normal human 
erythrocytes produced in normal physiological conditions and thus represent a microcytic 
population393. This contrasts to the earlier demonstration of the differentiation of normal sized 
erythrocytes following extended IH explant culture in iron-enriched MCDB media20. 
Administration of iron during IHEDC culturing (i.e., in RPMI with 1μM Fe or in MCDB), did not 
correct the microcytosis (data not shown), indicating that the requirement for iron in the 
manufacture of haemoglobin, precedes the blast-like stage. This observation provides insights 
into the biological processes and timing of the development and optimal intervention of iron 
deficiency anaemia. Future study would involve investigation into the onset of haemoglobin 
expression using a haemoglobin-specific antibody at various stages of blast differentiation. 
Likewise, it would be interesting to observe if differences arose in the differentiation of IHEDCs 
from IH explants cultured in RPMI media, RPMI media enriched with 1μM iron and MCDB 
media. Such a study would be useful in determining the temporal requirements of essential 
factors such as iron. 
Culture of IHEDCs in MCDB media promotes greater cell expansion under all experimental 
conditions compared with RPMI media alone or RPMI enriched with iron. This highlights the 
composition of MCDB media including factors, in addition to iron, that promote blast 
proliferation. Copper for instance, present in MCDB media, may contribute to enhanced IHEDC 
proliferation. Whilst there is incomplete understanding of the role of copper in erythropoiesis, 
copper deprivation results in a microcytic, hypochromic anaemia394 with symptoms mimicking 
those of myelodysplastic syndrome395-398 Further investigation using this model into the role 




of copper in erythropoiesis, its potential synergistic action with iron, may lead to improved 
therapy for iron deficiency anaemia.  
5.1.4.2 Effects of Short Chain Fatty Acids in the Culture of Infantile Haemangioma Explant-
Derived Cells  
Propionic acid and more significantly butyric acid, promote proliferation of blast-like structures 
from IHEDCs within 24 hours in culture. Whilst IHDECs cultured in MCDB media generate the 
highest cell counts, the addition of 1μM FeSO4 to RPMI media significantly increased cell counts 
after 24 hours. Most notably, cell counts following administration of propionic acid at 24 hours 
are comparable with IHEDCs cultured in RPMI enriched with 1μM FeSO4 or MCDB media. This 
indicates that the proliferative effect of propionic acid in culture could be enhanced by the 
addition of iron, highlighting a potential relationship between the activity of iron and propionic 
acid.  
Itinteang et al.20 have demonstrated spontaneous in vitro erythrocyte production from IH 
explant culture, following five months in culture. The demonstration of the generation of 
erythrocytes from IHEDCs in culture within 72 hours in the presence propionic acid, is 
particularly notable. The efficacy of propionic acid in expediting erythrocyte differentiation 
using the IH explant model, observed in this pilot study, represents a novel finding. Due to the 
nature of this pilot study conclusive evidence as to the capability of butyric acid in inducing a 
similarly efficient differentiation was not available and thus future investigations are required. 
The finding of activated STAT proteins in proliferating IH, suggests that the JAK-STAT pathway 
may play a role in mediating SCFA-induced erythrocytic differentiation of IHEDCs, similar to the 
SCFA-induced differentiation observed by other groups using other models315, 316. 
5.1.4.3 Morphology and Characterisation of Infantile Haemangioma Explant-Derived Cells  
IHEDCs arising within days of IH explant culture exhibit a fibroblast-like multipolar morphology 
with multiple cytoplasmic projections, consistent with previous reports23. As MSCs extracted 
from homogenates of IH tissue demonstrate a fibroblast-like morphology18 consistent with 
human bone marrow derived MSC399, it may be proposed that IHEDCs emanating from the 
explants early in culture may represent a MSC population. The population of uniform rounded 
nucleated IHEDCs emerging subsequently and further away from the IH explant tissue, may 
represent a progeny of these fibroblast-like IHEDCs rather than a distinct population derived 
directly of the explant tissue. 




5.1.4.4 Links to Previously Reported Blast Colony Forming Cells  
A population of EPCs has been previously identified within IH22 and the IHEDC-derived blast-
like structures demonstrated by Itinteang et al.49, are consistent with this population. As the 
markers used to identify this EPC phenotype, VEGFR-2, CD34, CD133 and ACE, are also 
expressed on haemangioblasts, it is difficult to conclude as to whether these blast-like 
structures represent a haemangioblast population or an EPC population derived from 
haemangioblasts.  
The hierarchical development of endothelial and haematopoietic progenies from a bi-potential 
precursor has been well elucidated 14, 134, 147, 157, 158, 164, 400 is well documented. Comparison of 
IHEDC-derived blast-like structures with those observed by other groups suggests that IHEDC-
derived blast-like structures represent an endothelial intermediate derived from 
haemangioblasts that retains primitive haematopoietic potential. Kennedy et al.164 reported 
BL-CFCs arising in culture with macrophage lineage potential. There is notable similarity 
between the morphology of these macrophage producing BL-CFCs and the blast-like structures 
achieved in the present study. Likewise blast-like structures observed following IHEDC culture 
are comparable to the mature blast-like colonies arising at day 12 of hESC culture reported by 
Choi et al.14. These mature blast-like colonies retained erythroid, megakaryocytic and 
macrophage lineage differentiation potential14. The lack of the more up-stream 
haemangioblast population observed by Choi et al14 suggests, that whilst representing 
primitive posterior mesoderm derivatives, IHEDCs harvested from tissue culture may represent 
a more down-stream population. Based on the findings of other groups14, 158, 164, it is possible 
that other haematopoietic lineages can be generated from IHEDCs in culture. 
5.2 Limitations of This Study 
5.2.1 Tissue Heterogeneity 
Clinically IH consists of proliferative, involuting and involuted phases in a continuum and IH 
samples used for this study were obtained across this spectrum of IH development rather than 
three distinct biological phases. Involution of IH occurs gradually and is not uniform throughout 
the lesion with regions of proliferation and involution within close proximity. 
This is inconsequential for IHC analysis as morphology is readily identifiable. In the case of 
mRNA for NanoString analysis and protein for 1DE-WB, tissues that were homogenised for 




extraction may not truly represent the overall clinical phases of IH development. Thus, it is 
important to consider tissue heterogeneity when interpreting the results of both the 1DE-WB 
and NanoString analyses. This heterogeneity, may explain the lack of statistical significance 
between mRNA levels of both STAT3 and STAT5 in the proliferative and involuted phases of IH.  
5.2.2 Time Restraints  
Another limitation of this study is the limited time period available to complete the BMedSci 
project. Since the serendipitous discovery of accelerated involution of IH induced by 
propranolol38 and acebutalol 39 in 2008, propranolol is now widely used as first line 
pharmacological treatment for IH54, 401-406. Because of the efficacy of propranolol therapy, 
proliferating IH tissue samples from a total of two patients were available for culture, over the 
duration of this study. IHEDC numbers required for experimental culture with SCFA, were only 
achieved from one of these two tissue samples in the available time to conduct a pilot 
functional study. Verification of the findings of this functional study requires a increase in IH 
samples for culture experiments allowing the replication of results.  
5.3  Future Directions 
The preliminary results of this in vitro study is exciting and require validation by increasing the 
number of tissue samples from other IH cases. The use of iPSC technology may be useful in 
providing haemangioblast derived blast-like structures (equivalent to blast-like strictures 
observed in the present study49 for further validation of the SCFA-induced proliferation and 
differentiation observed of the blast-like structures and terminal erythrocytic differentiation 
observed in this study. Investigations to extend the findings of the present study are discussed 
below.  
5.3.1 Characterisation of Infantile Haemangioma Explant-Derived Cells 
Characterisation of IHEDCs arising from IH explants at various time points of IH explant culture 
to demonstrate their expression profile would reveal the innate physiology of the lesion. 
Previous report on the differentiation of IHEDCs into osteoblasts and adipocytes19, may 
represent down-stream progenies of IHEDCs with fibroblast-like morphology that emanate 
early from the IH explants. Such investigation may separate a population of IHEDCs with 
fibroblast-like morphology possessing multi-potential capacity, compared with those IHEDCs 




arising subsequently that may represent a more differentiated haemangioblast population. 
FACs analysis may identify all cell types and their relative abundance arising from IH explant 
culture. This would provide greater insight into the innate differentiation pathways of IHEDCs.  
5.3.2 Administration of SCFAs and Activation of STAT Proteins 
The extraction of protein from SFCA-treated IHEDCs would allow 1DE-WB semi-quantitative 
analysis for comparisons between the levels of STAT activation between different culture 
conditions and control samples at various time points.  
Recently developed software allows analysis of IF IHC staining and IF ICC staining to investigate 
protein expression levels in individual cells with the ability to determine if the protein is 
localised to the nucleus, cytoplasm or membrane depending on the counter-stain/antibody 
used. Such a technique can also determine the levels of co-expression between two antibodies 
of interest. Such capabilities could enable comparisons between the relative intensities of 
fluorescence (and thus protein expression) within the IH explants. Such techniques would allow 
analysis of the co-localisation of STAT proteins with stem cell markers and other markers such 
as EPOR and ACE, to elucidate more clearly the interactions hypothesised in this study. Co-
localisation assessment may also be applied to the investigation of SCFA-treated IH explants, 
although tissue morphology is somewhat altered in IHC following explant culture. 
5.3.3 Secretion of Proteases from Infantile Haemangioma Explant-Derived Cells 
In this study, on-going liquefaction of Matrigel occurred when IHEDCs were cultured under 
experimental negative control conditions, presumably due to active secretion of protease(s) 
from IHEDCs in vitro. A role for these proteases, in the propranolol-induced apoptosis of IHEC 
and consequently the involution of the lesion has recently been suggested349, 350. Similarly, a 
number of proteases involved in molecular pathways regulating the biology of IH, have been 
identified by Itinteang et al.407, 408. The analysis of supernatant/conditioned media from IHEDC 
culture, using a protease enzyme activity assay kit, may enable identification of relevant 
proteases. 




5.4 Significance of the Findings of this Study 
5.4.1 Validation of Infantile Haemangioma as a Model for Human Erythropoiesis  
The demonstration of haematopoietic differentiation of IHEDCs into blast-like structures 
supports the haematopoietic capability of the HE in IH. This validates IH as a useful human 
model for haematopoiesis. The in vitro generation of microcytic erythrocytes under iron-
depleted conditions further underscores in vivo physiology.  
Despite widespread uptake of the iPSC technology9, 11, 12 and in the development of ex vivo 
models of production of blood products208, IH represents a useful human-specific model for 
studying primitive haematopoiesis. An understanding of the molecular mechanisms controlling 
primitive haematopoiesis occurring within IH tissue in vivo and in vitro may enable progress in 
the generation of haematopoietic precursors using iPSC technology.  
5.4.2 The Role of Primitive Cells in Tumour Biology 
Alongside the demonstration of stem cells in the biology of IH, there is an increasing body of 
evidence of the role of stem cells in the biology of tumour, in general. The demonstration of 
haematopoietic differentiation capability of IHEDCs and the involvement of the JAK-STAT 
pathway in IH, adds to mounting evidence of a critical role for stem cells in this enigmatic 
tumour.  
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6 Chapter 6 Conclusion 
Stem cells play a critical role in the biology of IH. There is increasing evidence that IH is due to 
aberrant proliferation and differentiation of a HE regulated by the RAS. This HE possesses a 
functional capacity for neuronal17, mesenchymal19 ,endothelial15, 49 and haematopoietic20 
differentiation. The ultimate involution of IH is characterised by terminal differentiation of 
mesenchymal precursors resulting in fibro-fatty the deposition15, 18. Whilst the activation of 
the components of the JAK-STAT pathway throughout proliferating IH may simply reflect the 
high levels of plasticity of the primitive cells, it is more likely that the activity of this regulatory 
pathway reflects the complex nature of IH biology, namely the interactions of stem cells and 
their progenies within the unique tumour microenvironment. The expression of pSTAT1 and 
pSTAT3 within IH reflects the activity of HSCs and stem cell maintenance respectively, whilst 
pSTAT5 signalling down-stream of the EPOR reflects the haematopoietic activity of the lesion 
in its proliferative phase. The functional capacity of the HE within IH is supported by a 
functional capacity to form erythrocytes from IHEDCs in vitro. This functional erythropoietic 
differentiation capacity can be enhanced and expedited by the administration of ultra-low 
concentrations of SCFAs, butyric acid or propionic acid, with generation of enucleated 
erythrocytes within 72 hours of administration. Furthermore, the differentiation environment 
can be manipulated to mimic the in vivo situation. The ability to generate microcytic 
erythrocytes under iron-deprived conditions further underscores that in vitro erythropoiesis 
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